<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70555</article-id><article-id pub-id-type="doi">10.7554/eLife.70555</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>The oxygen sensor prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-239374"><name><surname>Ajouaou</surname><given-names>Yousra</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1734-6505</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241732"><name><surname>Azouz</surname><given-names>Abdulkader</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271070"><name><surname>Taquin</surname><given-names>Anaëlle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266173"><name><surname>Denanglaire</surname><given-names>Sebastien</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241734"><name><surname>Hussein</surname><given-names>Hind</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266174"><name><surname>Krayem</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-160220"><name><surname>Andris</surname><given-names>Fabienne</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8644-1020</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241735"><name><surname>Moser</surname><given-names>Muriel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-189325"><name><surname>Goriely</surname><given-names>Stanislas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-160307"><name><surname>Leo</surname><given-names>Oberdan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3621-4743</contrib-id><email>oberdan.leo@ulb.be</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01r9htc13</institution-id><institution>U-CRI (ULB Center for Research in Immunology), Université Libre de Bruxelles (ULB)</institution></institution-wrap><addr-line><named-content content-type="city">Charleroi</named-content></addr-line><country>Belgium</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01r9htc13</institution-id><institution>Immunobiology Laboratory, Université Libre de Bruxelles (ULB)</institution></institution-wrap><addr-line><named-content content-type="city">Charleroi</named-content></addr-line><country>Belgium</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01r9htc13</institution-id><institution>Institute for Medical Immunology, Université Libre de Bruxelles (ULB)</institution></institution-wrap><addr-line><named-content content-type="city">Charleroi</named-content></addr-line><country>Belgium</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01r9htc13</institution-id><institution>Department of Radiation Oncology, Institut Jules Bordet, Université Libre de Bruxelles</institution></institution-wrap><addr-line><named-content content-type="city">Brussels</named-content></addr-line><country>Belgium</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01r9htc13</institution-id><institution>Laboratory of Clinical and Experimental Oncology (LOCE), Institut Jules Bordet, Université Libre de Bruxelles</institution></institution-wrap><addr-line><named-content content-type="city">Brussels</named-content></addr-line><country>Belgium</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ratcliffe</surname><given-names>Peter J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>22</day><month>02</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e70555</elocation-id><history><date date-type="received" iso-8601-date="2021-06-12"><day>12</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-02-18"><day>18</day><month>02</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-03-23"><day>23</day><month>03</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.03.23.436597"/></event></pub-history><permissions><copyright-statement>© 2022, Ajouaou et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Ajouaou et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70555-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-70555-figures-v2.pdf"/><abstract><p>The oxygen sensor prolyl hydroxylase domain 2 (PHD2) plays an important role in cell hypoxia adaptation by regulating the stability of HIF proteins (HIF1α and HIF2α) in numerous cell types, including T lymphocytes. The role of oxygen sensor on immune cells, particularly on regulatory T cell (Treg) function, has not been fully elucidated. The purpose of our study was to evaluate the role of PHD2 in the regulation of Treg phenotype and function. We demonstrate herein that selective ablation of PHD2 expression in Treg (PHD2<sup>ΔTreg</sup> mice) leads to a spontaneous systemic inflammatory syndrome, as evidenced by weight loss, development of a rectal prolapse, splenomegaly, shortening of the colon, and elevated expression of IFN-γ in the mesenteric lymph nodes, intestine, and spleen. PHD2 deficiency in Tregs led to an increased number of activated CD4 conventional T cells expressing a Th1-like effector phenotype. Concomitantly, the expression of innate-type cytokines such as <italic>Il1b</italic>, <italic>Il12a</italic>, <italic>Il12b,</italic> and <italic>Tnfa</italic> was found to be elevated in peripheral (gut) tissues and spleen. PHD2<sup>ΔTreg</sup> mice also displayed an enhanced sensitivity to dextran sodium sulfate-induced colitis and toxoplasmosis, suggesting that PHD2-deficient Tregs did not efficiently control inflammatory response in vivo, particularly those characterized by IFN-γ production. Further analysis revealed that Treg dysregulation was largely prevented in PHD2-HIF2α (PHD2-HIF2α<sup>ΔTreg</sup> mice), but not in PHD2-HIF1α (PHD2-HIF1α<sup>ΔTreg</sup> mice) double KOs, suggesting an important and possibly selective role of the PHD2-HIF2α axis in the control of Treg function. Finally, the transcriptomic analysis of PHD2-deficient Tregs identified the STAT1 pathway as a target of the PHD2-HIF2α axis in regulatory T cell phenotype and in vivo function.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>regulatory T cell</kwd><kwd>oxygen sensor</kwd><kwd>inflammation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008530</institution-id><institution>European Regional Development Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ajouaou</surname><given-names>Yousra</given-names></name><name><surname>Hussein</surname><given-names>Hind</given-names></name><name><surname>Andris</surname><given-names>Fabienne</given-names></name><name><surname>Moser</surname><given-names>Muriel</given-names></name><name><surname>Goriely</surname><given-names>Stanislas</given-names></name><name><surname>Leo</surname><given-names>Oberdan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Fond de la recherche scientifique</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ajouaou</surname><given-names>Yousra</given-names></name><name><surname>Hussein</surname><given-names>Hind</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Walloon region</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Andris</surname><given-names>Fabienne</given-names></name><name><surname>Moser</surname><given-names>Muriel</given-names></name><name><surname>Goriely</surname><given-names>Stanislas</given-names></name><name><surname>Leo</surname><given-names>Oberdan</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Fond Jean Brachet</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Andris</surname><given-names>Fabienne</given-names></name><name><surname>Moser</surname><given-names>Muriel</given-names></name><name><surname>Goriely</surname><given-names>Stanislas</given-names></name><name><surname>Leo</surname><given-names>Oberdan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The prolyl hydroxylase domain 2 regulates the Treg development and function in a hypoxia-inducible factor 2α-dependent manner.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>CD4<sup>+</sup> regulatory T cells (Tregs), accounting for approximately 5–10% of total circulating CD4<sup>+</sup> T cells, represent a critical subset of T lymphocytes involved in immune homeostasis. Through a broad set of effector mechanisms, these cells contribute to immune tolerance to self-constituents and to mucosal antigens derived from the commensal microflora and food (<xref ref-type="bibr" rid="bib39">Lu et al., 2017</xref>; <xref ref-type="bibr" rid="bib72">Xing and Hogquist, 2012</xref>). Tregs also participate in the resolution of inflammatory responses (<xref ref-type="bibr" rid="bib17">Dominguez-Villar and Hafler, 2018</xref>) and play an important role in maternal immunotolerance against the semi-allogeneic fetus (<xref ref-type="bibr" rid="bib55">Samstein et al., 2012</xref>). While critical to maintain tissue integrity, excessive activation of Tregs impedes adequate immune responses to tumors and pathogens, suggesting a tight control of their suppressive activity and tissue localization (<xref ref-type="bibr" rid="bib63">Togashi et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Aandahl et al., 2004</xref>; <xref ref-type="bibr" rid="bib64">van der Burg et al., 2007</xref>). Although uniformly characterized by the expression of the lineage-specific, Foxp3 transcription factor (<xref ref-type="bibr" rid="bib39">Lu et al., 2017</xref>), regulatory T cells display a wide range of phenotypic and functional properties that allow them to migrate to specific sites and suppress a variety of immune reactions, including inflammatory (<xref ref-type="bibr" rid="bib9">Caridade et al., 2013</xref>) and humoral responses (<xref ref-type="bibr" rid="bib12">Clement et al., 2019</xref>). Although diverse, the mechanisms whereby Tregs antagonize the activity of immune effectors are largely paracrine in nature (<xref ref-type="bibr" rid="bib65">Vignali et al., 2008</xref>). Short-range suppressive mechanisms include competition for nutrients and/or growth factors (mostly cytokines), secretion of immunosuppressive factors, and direct, contact-mediated, inactivation of antigen-presenting cells (<xref ref-type="bibr" rid="bib67">Wardell et al., 2021</xref>). These findings suggest that Tregs have to adapt to multiple lymphoid and nonlymphoid environments and suppress immune responses in a context and tissue-dependent fashion (<xref ref-type="bibr" rid="bib58">Shevyrev and Tereshchenko, 2019</xref>; <xref ref-type="bibr" rid="bib50">Panduro et al., 2016</xref>).</p><p>Oxygen represents an essential component of cellular bioenergetics and biochemistry. Because oxygen tension varies according to tissues and pathophysiological states (<xref ref-type="bibr" rid="bib2">Ast and Mootha, 2019</xref>), cells need to adapt to fluctuations in oxygen availability in order to maintain an adequate functional and metabolic status. Of note, low-oxygen availability (hypoxia) plays a critical role in the pathophysiology of many immune disorders (<xref ref-type="bibr" rid="bib44">McKeown, 2014</xref>; <xref ref-type="bibr" rid="bib4">Bartels et al., 2013</xref>). Inflammation, in particular, is thought to reduce oxygen availability to tissues by affecting microvascular form and function, and through the recruitment of highly oxygen-consuming inflammatory cells producing NADPH oxidase-derived reactive oxygen species (<xref ref-type="bibr" rid="bib48">Nanduri et al., 2015</xref>).</p><p>Immune cells patrolling through lymphoid and nonlymphoid tissues need therefore to readily adapt to varying oxygen concentration levels in order to exert their function (<xref ref-type="bibr" rid="bib45">Mempel and Marangoni, 2019</xref>), suggesting an important role for oxygen sensors in immune regulation. Several hypoxia-sensitive pathways are known to enable single-cell survival in low-oxygen settings. In particular, reduced oxygen levels are directly sensed by a family of oxygen-dependent prolyl hydroxylases (PHD encoded by <italic>Egln gene,</italic> comprising three members) (<xref ref-type="bibr" rid="bib27">Hirota, 2020</xref>), although other mechanisms mediated by oxygen-sensitive histone lysine demethylases (KDM) and the cysteamine dioxygenase/N-degron pathway have been recently uncovered (<xref ref-type="bibr" rid="bib3">Baik and Jain, 2020</xref>). Hypoxia-inducible factors (HIFs), a set of evolutionary conserved transcriptional regulators, represent the best-described substrates of PHDs. These factors are heterodimers composed of a HIFα subunit whose stability is directly controlled by oxygen availability and a constitutively expressed HIF1β subunit (also known as ARNT) (<xref ref-type="bibr" rid="bib66">Wang and Semenza, 1995</xref>). Following the initial characterization of the first member of HIFα family (HIF1α), two additional members, HIF2α and HIF3α, have been identified and shown to be similarly regulated by O<sub>2</sub> availability and bind to HIF1β (<xref ref-type="bibr" rid="bib69">Webb et al., 2009</xref>). In normoxia, PHDs, whose affinity for oxygen is low and comparable to atmospheric concentrations, catalyze the prolyl-hydroxylation of HIFα subunits (<xref ref-type="bibr" rid="bib56">Semenza, 2001</xref>). This post-translational modification allows recognition and ubiquitination of HIFα subunits by the E3 ubiquitin ligase Von Hippel–Lindau protein (pVHL) and subsequent degradation by the proteasome (<xref ref-type="bibr" rid="bib42">Maxwell et al., 1999</xref>). In hypoxia, nonhydroxylated alpha subunits escape degradation and translocate to the nucleus where they bind to constitutively expressed and stable beta subunits to constitute an active heterodimer able to regulate gene expression. This process promotes transcriptional regulation of numerous genes, ultimately leading to increased oxygen supply (such as angiogenesis) and promotion of anaerobic metabolism (<xref ref-type="bibr" rid="bib18">Downes et al., 2018</xref>).</p><p>Multiple levels of complexity of this major regulatory axis have been recently uncovered. As previously suggested, the presence of several members of the PHD and HIF families suggests specialized functions of PHD-HIF pairs during ontogeny and in selected tissues (<xref ref-type="bibr" rid="bib68">Watts and Walmsley, 2019</xref>). In particular, while HIF1α appears as ubiquitously expressed in all metazoans, HIF2α represents a late acquisition of vertebrates, displaying a more restricted tissue expression pattern (<xref ref-type="bibr" rid="bib61">Talks et al., 2000</xref>). Although these factors bind to similar sequence motifs (hypoxia response elements [HREs]) and regulate the expression of a shared set of genes, both HIF1α and HIF2α-specific gene targets have been identified in multiple tissues (<xref ref-type="bibr" rid="bib18">Downes et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Hu et al., 2007</xref>; <xref ref-type="bibr" rid="bib8">Bono and Hirota, 2020</xref>). Further complexity in this pathway stems from the possible occurrence of additional, non-HIF-related, PHD substrates (<xref ref-type="bibr" rid="bib46">Meneses and Wielockx, 2016</xref>; <xref ref-type="bibr" rid="bib47">Mikhaylova et al., 2008</xref>; <xref ref-type="bibr" rid="bib10">Chan et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Romero-Ruiz et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Huo et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Xie et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Lee et al., 2015b</xref>; <xref ref-type="bibr" rid="bib24">Guo et al., 2016</xref>), a set of findings that however has not been confirmed in more rigorous in vitro settings using well-defined synthetic substrates (<xref ref-type="bibr" rid="bib14">Cockman et al., 2019</xref>).</p><p>Hypoxia plays a dual role in inflammation and in the regulation of immune responses. In most settings, hypoxia promotes inflammation, while in some instances, such as in tumor sites, low oxygen levels generally cause unresponsiveness of immune effectors, thus favoring tumor growth. The often-opposing effects displayed by HIF activation on the activity of immune cells equally match this complexity (<xref ref-type="bibr" rid="bib15">Corrado and Fontana, 2020</xref>). Previous work has indeed highlighted the important role of the PHD-HIF axis in regulating both innate and adaptive immune effectors (<xref ref-type="bibr" rid="bib68">Watts and Walmsley, 2019</xref>). The role of HIF1α in regulating T cell activity has been described in many studies and is mainly linked to the capacity of this hypoxia-induced transcription factor to promote glycolysis (for a review, see <xref ref-type="bibr" rid="bib43">McGettrick and O’Neill, 2020</xref>). Accordingly, HIF1α expression favors the development of highly glycolytic inflammatory Th17 cells, while inhibiting the development of Tregs, which rely mostly on aerobic metabolism (<xref ref-type="bibr" rid="bib59">Shi et al., 2011</xref>). HIF1α also plays a direct role in Th17 development, through the transcriptional activation of <italic>Rorc</italic> (<xref ref-type="bibr" rid="bib16">Dang et al., 2011</xref>). The role of HIF1α in Th1 development appears as more complex and context-dependent. Hypoxia decreases IFN-γ production of Th1-like cells in a HIF1α-dependent fashion (<xref ref-type="bibr" rid="bib57">Shehade et al., 2015</xref>), while sustained expression of this transcription factor in normoxia (as observed in mice lacking PHDs expression; <xref ref-type="bibr" rid="bib13">Clever et al., 2016</xref>) leads to an increase in IFN-γ-secreting CD4<sup>+</sup> T cells. Of note, expression of HIF1α can be upregulated in normoxia both by TCR (<xref ref-type="bibr" rid="bib40">Lukashev et al., 2001</xref>) and cytokine-initiated signals (<xref ref-type="bibr" rid="bib16">Dang et al., 2011</xref>), confirming that HIF1α may play a role in Th1 cells development both in hypoxia and normoxia.</p><p>The role of hypoxia-induced factors in Treg development and function is presently not fully elucidated. As previously discussed, HIF1α deficiency improves Treg cell development, possibly a consequence of the limited requirement for glycolysis of this cell subset (<xref ref-type="bibr" rid="bib59">Shi et al., 2011</xref>). However, hypoxia promotes Foxp3 expression in a HIF1α-dependent fashion (<xref ref-type="bibr" rid="bib6">Ben-Shoshan et al., 2008</xref>) and expression of HIF1α is required for adequate regulatory T cell function (<xref ref-type="bibr" rid="bib11">Clambey et al., 2012</xref>). Similarly, a recent report has identified HIF2α as an important mediator of Treg function in vivo, further stressing the important role of these hypoxia-induced factors in the control of in vivo inflammatory manifestations (<xref ref-type="bibr" rid="bib28">Hsu et al., 2020</xref>). In agreement with these conclusions, PHD proteins have also been shown to play a role in the differentiation of peripheral (but not thymic-derived) Tregs (<xref ref-type="bibr" rid="bib13">Clever et al., 2016</xref>). Expression of these proteins appears to redundantly regulate Th1 vs. iTreg development, mostly by limiting the accumulation of HIF1α. In contrast to this study, a recent publication has highlighted a selective role of the PHD2 isoform in the regulation of Treg function (<xref ref-type="bibr" rid="bib73">Yamamoto et al., 2019</xref>). ShRNA-mediated knockdown of PHD2 expression in Foxp3-expressing cells (PHD2-KD Tregs) led to a systemic inflammatory syndrome characterized by mononuclear cell infiltration in several organs. PHD2-KD Tregs displayed reduced suppressive capacities both in vitro and in vivo, suggesting an important and intrinsic role of PHD2 in this cell subset. Of interest, loss of HIF2α expression reversed the phenotype of these mice bearing PHD2-KD Tregs, suggesting an important role of the PHD2-HIF2α axis in regulating Treg function.</p><p>To better delineate the role of PHD2, HIF1α, and HIF2α in the regulation of Treg development and function, we have generated a set of conditional mouse strains lacking expression of these hypoxia-responsive proteins in Foxp3<sup>+</sup> cells. Using these tools, we confirm herein that mice in which expression of PHD2 is selectively inactivated in regulatory T cells display a spontaneous inflammatory syndrome characterized by altered immune homeostasis at the steady state and high sensitivity to Th1-type inflammatory diseases. This proinflammatory phenotype was accentuated by the concomitant loss of PHD2 and HIF1α, but almost completely alleviated in mice dually deficient for PHD2 and HIF2α. Transcriptome analysis confirmed a marginal role for HIF1α-dependent enhanced glycolysis in the regulation of Treg function and allowed us to identify STAT1 as a potential target of the PHD2-HIF2α axis in maintaining immune homeostasis and preventing excessive Th1-mediated inflammation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Deletion of PHD2 in Tregs leads to a systemic, type 1-like, inflammatory syndrome associated to altered Treg numbers and phenotype</title><p>Based on the predominance of <italic>Egln1</italic> (PHD2) expression in Tregs over other members of the PHD family, we generated a mouse strain lacking PHD2 expression in Tregs (identified as PHD2<sup>ΔTreg</sup>) (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), as described in Materials and methods. These mice displayed a strongly reduced expression of <italic>Egln1</italic> mRNA in Tregs, while retaining control level expression of this enzyme in other, non-Treg spleen and peripheral lymph node cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Upregulation of GLUT1 expression, a well-known target of HIF1α, was also only found in Foxp3-expressing cells in these mice, further supporting the selective depletion of PHD2 in Tregs vs. T convs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). While fertile and viable, over 70% of these mice developed a spontaneous inflammatory syndrome, characterized by weight loss, episodes of anal prolapse, reduced colon length, splenomegaly, and hemorrhagic abdomen (<xref ref-type="fig" rid="fig1">Figure 1a–e</xref>). This last feature is most likely due to an increased blood hematocrit (with enhanced numbers of circulating red blood cells) associated to an elevation in vascular permeability, as shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>. Although the frequency of CD4<sup>+</sup> and CD8<sup>+</sup> conventional T lymphocytes (see <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> for gating strategy) in several lymphoid organs was not significantly altered in PHD2<sup>ΔTreg</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1f</xref>), the total number of CD4<sup>+</sup> cells was increased in the peripheral lymphoid organs of these mice (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Moreover, these lymphocytes displayed clear signs of spontaneous activation, as evidenced by the significant increase in the expression of markers (i.e., CD44) associated to an effector-like phenotype (<xref ref-type="fig" rid="fig1">Figure 1g and h</xref>). Confirming these findings, intracellular staining of short-term stimulated T cells (using pharmacological agents bypassing TCR signaling) revealed an increased capacity of conventional T cells from PHD2<sup>ΔTreg</sup> mice to produce IFN-γ, while retaining control-like production of IL-17 (<xref ref-type="fig" rid="fig1">Figure 1i</xref>). The ex vivo evaluation of mRNA abundance in whole, unfractionated, mesenteric lymph nodes (mLNs) similarly showed a significantly elevated expression of type 1-associated adaptive and innate cytokines, including <italic>Ifng</italic>, <italic>Il1b,</italic> both <italic>Il12</italic> subunits, and <italic>Tnfa</italic> (<xref ref-type="fig" rid="fig1">Figure 1j</xref>). Overall, these observations point to the establishment of a Th1-like, proinflammatory environment in mice possessing PHD2-deficient Tregs.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>PHD2<sup>ΔTreg</sup> mice display a spontaneous Th1-like inflammatory syndrome.</title><p>(<bold>a</bold>) Body weight of naive mice was determined weekly. (<bold>b</bold>) At 12 weeks of age, male and female mice were examined for rectal prolapse. (<bold>c</bold>) Splenomegaly and colon length summarized in (<bold>d</bold>). (<bold>e</bold>) Representative gross autopsy of a hemorrhagic abdomen, (<bold>f–i</bold>) Lymphoid cells from spleen, mesenteric (mLN), peripheral (pLN) lymph nodes, or the small intestine lamina propria were collected from Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> mice. (<bold>f</bold>) Frequency of conventional, Foxp3- CD4 and CD8-expressing cells among TCRβ-expressing T lymphocytes. (<bold>g</bold>) Representative merged (n = 15) t-distributed stochastic neighbor embedding (t-SNE) plot after dimensionality reduction and unsupervised clustering of flow cytometry data from CD4-expressing spleen cells. Relative distributions of CD4<sup>+</sup> lymphocyte subsets are shown as doughnut charts. (<bold>h</bold>) Frequency of effector-like (CD44<sup>hi</sup> CD62L<sup>lo</sup>) conventional T lymphocytes in the indicated lymphoid organs. (<bold>i</bold>) Frequency of IFN-γ (top panel) and IL-17A (bottom panel) producing CD4<sup>+</sup> T cells after in vitro stimulation. (<bold>j</bold>) Expression of inflammatory cytokines determined by qPCR on extracts from unfractionated mLNs. Data are representative of at least three independent experiments with n = 9 (<bold>a, j</bold>), n = 25 (<bold>d</bold>), and n = 15 (<bold>f–i</bold>) per group. Values are presented as the mean ± SD and were compared by two-tailed unpaired Student’s <italic>t-</italic>test. Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. Naive Tconv: Foxp3<sup>-</sup> CD44<sup>-</sup> CD62L<sup>+</sup>; Memory Tconv: Foxp3<sup>-</sup> CD44<sup>+</sup> CD62L<sup>+</sup>; Effector Tconv: Foxp3<sup>-</sup> CD44<sup>+</sup> CD62L<sup>-</sup>; Memory Treg: Foxp3<sup>+</sup> CD44<sup>+</sup>CD62L<sup>+</sup>; Effector Treg: Foxp3<sup>+</sup> CD44<sup>+</sup>CD62L<sup>-</sup>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>PHD2<sup>ΔTreg</sup> mice display a spontaneous Th1-like inflammatory syndrome.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Treg-restricted loss of <italic>Egln1</italic> gene expression in PHD2<sup>ΔTreg</sup> mice.</title><p>(<bold>a</bold>) Treg cells from Foxp3<sup>cre</sup> male and female mice were purified by cell sorting from spleen (n = 10), mesenteric (mLN) (n = 8), peripheral (pLN) lymph nodes (n = 4), or the small intestine lamina propria (n = 4) and expression of <italic>Egln2</italic> (PHD1), <italic>Egln1</italic> (PHD2), and <italic>Egln3</italic> (PHD3) analyzed by qPCR. (<bold>b</bold>) YFP-positive (YFP<sup>+</sup>) and YFP-negative (YFP<sup>-</sup>) cells from PHD2-sufficient (Foxp3<sup>cre</sup> mice) and PHD2-deficient (PHD2<sup>ΔTreg</sup> mice) were purified by cell sorting from spleen and mLN and expression of <italic>Egln1</italic> analyzed by qPCR. The graph demonstrates selective loss of <italic>Egln1</italic> gene expression in Tregs, but not in Tconvs purified from PHD2<sup>ΔTreg</sup> mice. (<bold>c</bold>) <italic>Ifng</italic> gene expression relative to RPL32 by ex vivo-purified Tregs from spleen and mLN was determined by qPCR. (<bold>d</bold>) Representative flow cytometry expression profile of GLUT1, a specific HIF1α target gene in Foxp3-expressing or nonexpressing cells from Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> mice. (<bold>e</bold>) Frequency of GLUT1-expressing Tregs in lymphoid organs from Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> mice. Data are representative of two independent experiments with n = 6 per group. Values are presented as the mean ± SD and were compared by two-tailed unpaired Student’s <italic>t</italic>-test. Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Treg-restricted loss of <italic>Egln1</italic> gene expression in PHD2<sup>ΔTreg</sup> mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Increased blood cells counts and elevated hematocrit in PHD2<sup>ΔTreg</sup> mice associated with an increase in vascular permeability.</title><p>(<bold>a</bold>) White blood cell (WBC) counts, (<bold>b</bold>) red blood cell (RBC) counts, (<bold>c</bold>) platelet (PLT) counts, and (<bold>d</bold>) hematocrit (HCT) from Foxp3<sup>cre</sup>, PHD2<sup>ΔTreg</sup>, and PHD2-HIF2α<sup>ΔTreg</sup> male mouse blood. To assess vascular permeability, mice were i.v. injected with a 0.5% Evans blue solution, and the indicated, organs collected after 30 min and placed in formamide at 55°C during 24 hr. The absorbance of supernatants was measured at 600 nm, (<bold>e</bold>) Representative image of the colon supernatant after 24 hr in formamide, (<bold>f</bold>) ng of Evans blue per mg of tissue for spleen, mesenteric lymph nodes (mLN), colon, and liver of different groups of mice injected or not with Evans blue. Data are representative of two (<bold>a–d</bold>) or three (<bold>e, f</bold>) independent experiments with n = 7–9 per group (<bold>a–d</bold>) or n = 4–6 per group (<bold>e, f</bold>). Values are presented as the mean ± SD and were compared by one-way ANOVA (<bold>a–d</bold>) or two-way ANOVA (<bold>f</bold>) with Tukey’s multiple comparisons test. Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Increased blood cells counts and elevated hematocrit in PHD2<sup>ΔTreg</sup> mice associated with an increase in vascular permeability.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig1-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Gating strategy for flow cytometry data analysis.</title><p>Representative flow cytometry dot plots displaying the gating strategy for the identification of conventional T cell populations in <xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig3">3</xref>—<xref ref-type="fig" rid="fig5">5</xref> and for the identification of regulatory T cell subsets in <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref>, and <xref ref-type="fig" rid="fig8">Figure 8</xref> .</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Absolute cell counts.</title><p>Absolute cell counts of (<bold>a</bold>) CD4<sup>+</sup> T cells, (<bold>b</bold>) CD8<sup>+</sup> T cells, (<bold>c</bold>) regulatory T cells, and (<bold>d</bold>) activated conventional T cells in the spleen, mesenteric (mLN), peripheral (pLN) lymph nodes, and the small intestine lamina propria of Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> male and female mice. Data are representative of at least three independent experiments with n = 15 per group. Values are presented as the mean ± SD and were compared by two-tailed unpaired Student’s <italic>t</italic>-test. Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig1s4sdata1"><label>Figure 1—figure supplement 4—source data 1.</label><caption><title>Absolute cell counts.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig1-figsupp4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig1-figsupp4-v2.tif"/></fig></fig-group><p>Much to our surprise, flow cytometric analysis of lymphoid organs from naive animals revealed an increased frequency of Treg cells in the spleen, lymph nodes, and lamina propria of PHD2<sup>ΔTreg</sup> mice when compared to control animals (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). To evaluate the possible influence of PHD2 deletion on Treg development, thymic cell suspensions were analyzed for the expression of early Treg markers, including Foxp3, CD25, and CD24 (<xref ref-type="bibr" rid="bib49">Owen et al., 2019</xref>). Recent studies have revealed that mature Foxp3<sup>high</sup> CD25<sup>+</sup> Tregs can differentiate from two distinct thymic precursors identified as respectively CD25<sup>+</sup> Foxp3<sup>-</sup> and CD25<sup>-</sup> Foxp3<sup>low</sup> precursor Tregs (pre-Tregs). Analysis of thymic cell suspensions revealed an accumulation of the Foxp3<sup>low</sup> pre-Tregs and a reduction in the number of mature Tregs in PHD2-deficient, Foxp3-expressing cells, suggesting an early role for PHD2 in the generation of thymic-derived Tregs (<xref ref-type="fig" rid="fig2">Figure 2b and c</xref>). Accordingly, PHD2-deficient, Foxp3-expressing cells retained higher expression of CD24 (<xref ref-type="fig" rid="fig2">Figure 2d</xref>), a marker associated to a thymic immature state (<xref ref-type="bibr" rid="bib49">Owen et al., 2019</xref>), further confirming a putative role for PHD2 in the development of thymic-derived Tregs. No difference in the relative frequency of Treg subsets identified by the co-expression of Foxp3 with either naive and memory markers (<xref ref-type="fig" rid="fig2">Figure 2e</xref>) or with master transcription factors T-bet, GATA3, or RORγt (<xref ref-type="fig" rid="fig2">Figure 2f</xref>) was noted in these mice. The phenotype of splenic, PHD2-deficient Tregs was however significantly altered, showing a slight, but statistically significant, reduction in the expression of Foxp3 (<xref ref-type="fig" rid="fig2">Figure 2g</xref>), accompanied by reduced expression of the CD25, ICOS, and CD44 markers and enhanced expression of PD-1 (<xref ref-type="fig" rid="fig2">Figure 2h</xref>). Of note, neither CTLA-4 (<xref ref-type="fig" rid="fig2">Figure 2h</xref>) nor <italic>Il10</italic> (<xref ref-type="fig" rid="fig2">Figure 2i</xref>) expression was altered in PHD2-deficient Tregs. To evaluate the functional consequences of PHD2 deletion on peripheral Treg development, we generated Tregs from naive, conventional T cells using a well-established in vitro protocol. In keeping with in vivo observations, culture of CD4<sup>+</sup> T conv from PHD2<sup>ΔTreg</sup> mice led to a consistently higher yield of Foxp3-expressing cells when activated in the presence of Treg-inducing cytokines (<xref ref-type="fig" rid="fig2">Figure 2j and k</xref>). In contrast to their in vivo counterparts, these induced Tregs displayed control level expression of Foxp3 (<xref ref-type="fig" rid="fig2">Figure 2l</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Increased number, but altered phenotype of PHD2-deficient Treg cells.</title><p>Lymphoid cells from the thymus, spleen, mesenteric (mLN), and peripheral (pLN) lymph nodes were collected at 12 weeks of age from Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> male and female mice, and the relative frequency and phenotype of Foxp3-expressing cells were established by flow cytometry or qPCR. (<bold>a</bold>) Frequency of Foxp3-expressing cells among CD4-positive T lymphocytes. (<bold>b</bold>) Representative flow cytometry expression profiles of Foxp3 and CD25 expression among thymic CD4<sup>+</sup> T cells. (<bold>c</bold>) Frequency of mature-like (CD25<sup>+</sup> Foxp3<sup>+</sup>) and Treg precursors subsets identified respectively as CD25<sup>-</sup> Foxp3<sup>lo</sup> and CD25<sup>+</sup> Foxp3<sup>-</sup> cells among thymic CD4<sup>+</sup> T cells. (<bold>d</bold>) Frequency of immature-like, CD24<sup>+</sup> Foxp3<sup>+</sup> T cells in the thymus of adult mice. (<bold>e</bold>) Frequency of effector (CD62L<sup>low</sup> CD44<sup>high</sup>), memory (CD62L<sup>high</sup> CD44<sup>high</sup>), and naive (CD62L<sup>high</sup> CD44<sup>low</sup>) splenic Foxp3-expressing cells. (<bold>f</bold>) Frequency of splenic Tregs expressing the master transcription factors T-bet, GATA3, and RORγt. (<bold>g</bold>) Ratio of the Foxp3 MFI of PHD2-KO splenic Tregs to Foxp3<sup>cre</sup> splenic Tregs. (<bold>h</bold>) Expression of CD25, CD44, ICOS, PD-1, and CTLA-4 in splenic Treg of Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> mice. Top panel: representative traces of MFI. Bottom panel: ratios of the MFIs of PHD2-KO Treg to Foxp3<sup>cre</sup> Treg cells are expressed as the mean ± SD. (<bold>i</bold>) <italic>Il10</italic> gene expression relative to RPL32 by ex vivo-purified Tregs was determined by qPCR. (<bold>j–l</bold>) CD4<sup>+</sup> Foxp3<sup>-</sup> splenic naive T cells were stimulated in vitro with anti-CD3/CD28 (5/1 μg/ml) in the presence of TGF-β (3 μg/ml) and IL-2 (10 μg/ml) for 72 hr to induce Treg polarization. (<bold>j</bold>) Representative flow cytometry expression profiles of Foxp3 expression at the end of the culture period. The first panel represents a typical profile of cells activated in the absence of polarizing cytokines. (<bold>k</bold>) Number of Foxp3<sup>+</sup> cells generated in the culture conditions. (<bold>l</bold>) Expression (MFI) of Foxp3 by in vitro-induced Treg cells. Data are representative of at least two independent experiments with n = 15 (<bold>a, e–g</bold>) n = 9 (<bold>h, i</bold>) or n = 6 (<bold>c, d, k, l</bold>) per group. Values are presented as the mean ± SD and were compared by two-tailed unpaired Student’s <italic>t</italic>-test. Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Increased number, but altered phenotype of PHD2-deficient Treg cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig2-v2.tif"/></fig><p>To evaluate whether the altered phenotype of PHD2-deficient Tregs was a cell-autonomous phenomenon, heterozygous <italic>Foxp3</italic><sup>cre/+</sup> <italic>Egln1</italic><sup>fl/fl</sup> mice in which both PHD2-sufficient (YFP-negative) and PHD2-deficient (YFP-positive) Tregs coexist were examined (<xref ref-type="fig" rid="fig3">Figure 3</xref>). These mice did not display any sign of inflammation or hematological dysfunction and were morphologically (cf. weight, colon length, and spleen size) indistinguishable from Foxp3<sup>cre</sup> or Foxp3<sup>cre/+</sup> mice (this latter strain displaying the expected 1:1 ratio of YFP-pos:YFP-neg cells). Surprisingly, WT Tregs outcompeted PHD2-deficient Tregs in all compartments examined in <italic>Foxp3</italic><sup>cre/+</sup> <italic>Egln1</italic><sup>fl/fl</sup> mice (i.e., thymus, spleen, and peripheral lymph nodes, <xref ref-type="fig" rid="fig3">Figure 3a</xref>). A similar trend was observed following the transfer of an equal mix of WT and PHD2-deficient Tregs in <italic>Rag2</italic>-deficient mice (data not shown), strongly suggesting that PHD2 expression plays a role in Treg fitness and survival in the periphery. As previously shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>, PHD2-deficient Tregs expressed lower levels of Foxp3, CD25, and CD44, indicative of an intrinsic role of PHD2 in regulating Treg phenotype (<xref ref-type="fig" rid="fig3">Figure 3b–e</xref>). However, expression of CTLA-4 was not altered in PHD2-deficient Tregs (<xref ref-type="fig" rid="fig3">Figure 3b and f</xref>). Whether the altered fitness/ capacity to repopulate the periphery of PHD2-deficient Tregs is due to reduced expression of CD25 remains to be established.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Cell-autonomous role of PHD2 in determining Treg cells phenotype.</title><p>Spleen, thymus, mesenteric (mLN), and peripheral (pLN) lymph nodes were collected at 8 weeks of age from <italic>Foxp3</italic><sup>cre/+</sup><italic>Egln1</italic><sup>f/f</sup> heterozygous female mice, and the relative frequency and phenotype of Foxp3-expressing cells were established by flow cytometry. (<bold>a</bold>) Proportion of WT (YFP- cells) or PHD2-KO (YFP+ cells) Treg cells among Foxp3-expressing cells. (<bold>b</bold>) Representative histograms of Foxp3, CD25, CD44, and CTLA-4 expression in splenic WT Tregs (black lines) compared to splenic PHD2-KO Tregs (red lines). (<bold>c</bold>) Foxp3 MFI, (<bold>d</bold>) CD25 MFI, (<bold>e</bold>) CD44 MFI, and (<bold>f</bold>) CTLA-4 MFI of WT and PHD2-KO Tregs in lymphoid organs. Data are representative of two independent experiments with n = 9 per group. Values are presented as the mean ± SD and were compared by two-tailed unpaired Student’s <italic>t</italic>-test. Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Cell-autonomous role of PHD2 in determining Treg cells phenotype.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig3-v2.tif"/></fig></sec><sec id="s2-2"><title>In vivo-reduced suppressive function of PHD2-deficient Tregs</title><p>To evaluate the suppressive capacity of PHD2-deficient Tregs cells, ex vivo-purified CD45.2-expressing Tregs from control and PHD2<sup>ΔTreg</sup> mice were adoptively co-transferred into syngeneic Rag-deficient mice with CFSE-labeled, CD45.1-expressing CD4<sup>+</sup> naive T lymphocytes (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). In the absence of Tregs, transferred naive cells rapidly divided and acquired an effector-like phenotype, a well-established consequence of homeostatic proliferation in a lymphopenic environment (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). Addition of WT Tregs in the inoculum led to a significant reduction of conventional T cell proliferation and phenotype switch, while PHD2-deficient Tregs appeared functionally impaired in this assay (<xref ref-type="fig" rid="fig4">Figure 4b–d</xref>). Lack of suppressive activity of these Tregs was not a consequence of reduced viability and/or in vivo survival, as shown by the normal recovery rate of both Treg-populations at the time of assay readout (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). In contrast, when tested in vitro, PHD2-deficient Tregs consistently displayed a fully functional suppressive activity (<xref ref-type="fig" rid="fig4">Figure 4f and g</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Reduced in vivo but not in vitro suppressive capacity of PHD2-deficient Treg.</title><p>(<bold>a</bold>) Treg function was assayed following adoptive co-transfer of CD45.2 Foxp3-expressing cells with naive, CFSE-labeled congenic CD45.1 CD4<sup>+</sup> lymphocytes (Treg: Tconv ratio 1:3) into syngeneic lymphopenic male mice (<italic>Rag2</italic><sup>-/-</sup>). Recipient mice were euthanized at day 6 post-transfer, and their spleen and mesenteric lymph node (mLN) cells analyzed by flow cytometry. (<bold>b</bold>) Representative flow cytometry expression profiles of CFSE-labeled cells (CD45.1 gate in the spleen) with or without co-transferred Foxp3<sup>+</sup> cells from Foxp3<sup>cre</sup> or PHD2<sup>ΔTreg</sup> male mice. (<bold>c</bold>) Percentage of suppression established from CFSE staining profiles. (<bold>d</bold>) Frequency of activated (CD4<sup>+</sup> CD45.1<sup>+</sup> CD44<sup>hi</sup> CD62L<sup>lo</sup>) cells in the indicated lymphoid organs. (<bold>e</bold>) Frequency of Treg cells in the indicated organs 6 days post-transfer. (<bold>f, g</bold>) CFSE-labeled, naive conventional CD4<sup>+</sup> T cells from CD54.1 mice were co-cultured with ex vivo-purified Treg cells from Foxp3<sup>cre</sup> or PHD2<sup>ΔTreg</sup> mice at the indicated ratios in the presence of anti-CD3 antibodies (0.5 μg/ml) and splenic feeder cells. (<bold>f</bold>) Representative flow cytometry profiles of CSFE staining. (<bold>g</bold>) Percent of suppression of proliferation as compared to cultures in which Treg cells were omitted. Data are representative of three independent experiments with n = 15 (<bold>b–e</bold>) or n = 4 (<bold>f, g</bold>) per group. Values are presented as the mean ± SD and were compared by two-way ANOVA with Tukey’s multiple comparisons test (<bold>c–e</bold>) or two-tailed unpaired Student’s <italic>t</italic>-test (<bold>g</bold>). Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Reduced in vivo but not in vitro suppressive capacity of PHD2-deficient Treg.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig4-v2.tif"/></fig></sec><sec id="s2-3"><title>Increased susceptibility of PHD2<sup>ΔTreg</sup> mice to type 1 experimental inflammation</title><p>A series of experimental acute and chronic inflammatory models were employed to further evaluate the capacity of PHD2<sup>ΔTreg</sup> mice to sustain an in vivo inflammatory challenge. We first exposed mice to a chemical-induced colitis protocol. This assay revealed an increased sensitivity of PHD2<sup>ΔTreg</sup> mice to most dextran sodium sulfate (DSS)-induced inflammatory manifestations, including weight loss (<xref ref-type="fig" rid="fig5">Figure 5a</xref>), survival (<xref ref-type="fig" rid="fig5">Figure 5b</xref>), clinical score (<xref ref-type="fig" rid="fig5">Figure 5c</xref>), and colon length (<xref ref-type="fig" rid="fig5">Figure 5d</xref>). No difference was noted, however, in crypt morphology induced by DSS in both mouse strains (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). Similar observations were made when mice were acutely infected with <italic>Toxoplasma gondii</italic>, a model of infection-induced pathology (<xref ref-type="fig" rid="fig5">Figure 5f</xref>). Infected PHD2<sup>ΔTreg</sup> mice displayed increased weight loss (<xref ref-type="fig" rid="fig5">Figure 5g</xref>), reduced colon length (<xref ref-type="fig" rid="fig5">Figure 5h</xref>), and increased frequency of activated cells characterized by an effector-like phenotype (<xref ref-type="fig" rid="fig5">Figure 5i</xref>) and IFN-γ secretion capacity (<xref ref-type="fig" rid="fig5">Figure 5j</xref>). Infected PHD2<sup>ΔTreg</sup> mice also displayed a decrease in Treg T-bet<sup>+</sup> frequency, a population known to control Th1 inflammation during toxoplasmosis (<xref ref-type="bibr" rid="bib70">Wohlfert et al., 2020</xref>; <xref ref-type="fig" rid="fig5">Figure 5k</xref>). Overall, PHD2<sup>ΔTreg</sup> mice displayed an uncontrolled expansion of Th1-like cells following experimental toxoplasmosis. In contrast, both PHD2-deficient and -sufficient mouse strains were equally sensitive to enteritis induced upon injection of anti-CD3 antibodies (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), a model known to induce the predominant expansion of Th17-like, inflammatory effectors in vivo (<xref ref-type="bibr" rid="bib20">Esplugues et al., 2011</xref>). The role of uncontrolled IFN-γ secretion in mediating the proinflammatory status of this mouse strain was further confirmed by the observation that ubiquitous loss of <italic>Ifng</italic> gene expression largely reversed the phenotypical and cellular altered status of PHD2<sup>ΔTreg</sup> mice (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Increased sensitivity of PHD2<sup>ΔTreg</sup> mice to dextran sodium sulfate (DSS)-induced colitis and toxoplasmosis.</title><p>Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> male mice were provided with 2% DSS in tap water for 5 days. On day 5, the 2% DSS water was replaced with normal drinking water and mice were followed during 14 days for (<bold>a</bold>) body weight, (<bold>b</bold>) survival, (<bold>c</bold>) colitis severity, and (<bold>d</bold>) colon length. (<bold>e</bold>) Colons were isolated from untreated mice or 6 days after colitis induction and were fixed and stained with hematoxylin and eosin (H&amp;E); arrows indicate inflammatory cell infiltrates. (<bold>f</bold>) Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> male mice were infected by intragastric gavage with 10 cysts of ME-49 type II <italic>Toxoplasma gondii</italic> (control group are Foxp3<sup>cre</sup> mice without treatment) and subsequently followed for (<bold>g</bold>) body weight. (<bold>h</bold>) Mice were sacrificed 8 days after infection to assess colon length. (<bold>i</bold>) Frequency of effector-like (CD44<sup>hi</sup> CD62L<sup>lo</sup>) conventional T lymphocytes in the indicated lymphoid organs. (<bold>j</bold>) Frequency of IFN-γ-producing CD4<sup>+</sup> T cells after in vitro stimulation. (<bold>k</bold>) Frequency of T-bet<sup>+</sup> among Foxp3<sup>+</sup>(Treg) cells. Data are representative of three independent experiments with n = 20 (<bold>a, b</bold>), n = 10–14 (<bold>c, d</bold>), n = 5 (<bold>e</bold>), or n = 10 (<bold>g–k</bold>) per group. Values are presented as the mean ± SD and were compared by two-tailed unpaired Student’s <italic>t</italic>-test (<bold>a, c, g</bold>), by Mantel–Cox test (<bold>b</bold>), one-way ANOVA with Tukey’s multiple comparisons test (<bold>d, h</bold>) or two-way ANOVA with Tukey’s multiple comparisons test (<bold>i–k</bold>). Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Increased sensitivity of PHD2<sup>ΔTreg</sup> mice to dextran sodium sulfate (DSS)-induced colitis and toxoplasmosis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>PHD2<sup>ΔTreg</sup> mice display a near-normal response to anti-CD3-induced enteritis.</title><p>Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> female mice were injected twice i.p. with anti-CD3 mAbs (20 µg) at 2 days interval and weighted daily. (<bold>a</bold>) Weight loss was found similar in both mouse strains tested. (<bold>b</bold>) Relative expression of inflammatory mediators evaluated by qPCR on whole, unfractionated mesenteric lymph nodes. A similar, Th17-like response was observed in both mouse strains. Data are representative of two independent experiments with n = 6 per group. Values are presented as the mean ± SD and were compared by one-way ANOVA with Tukey’s multiple comparisons test. Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>PHD2<sup>ΔTreg</sup> mice display a near-normal response to anti-CD3-induced enteritis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Loss of <italic>Ifng</italic> gene expression attenuates the proinflammatory phenotype of PHD2<sup>ΔTreg</sup> mice.</title><p>PHD2<sup>ΔTreg</sup> mice were crossed with IFN-γKO mice (PHD2<sup>ΔTreg</sup> IFN-γ<sup>KO</sup> mice) and were compared to Foxp3<sup>cre</sup> and PHD2<sup>ΔTreg</sup> male and female mice and analyzed for (<bold>a</bold>) colon length, (<bold>b</bold>) frequency of effector-like (CD44<sup>hi</sup> CD62L<sup>lo</sup>) conventional T lymphocytes in the indicated lymphoid organs, (<bold>c</bold>) frequency of IFN-γ production after in vitro stimulation, (<bold>d</bold>) frequency of IL-17A-producing cells after in vitro stimulation, and (<bold>e</bold>) frequency of Foxp3<sup>+</sup> cells in the indicated lymphoid organs. Data are representative of three independent experiments with n = 10 per groups. Values are expressed as the mean ± SD and were compared by one-way ANOVA with Tukey’s multiple comparisons test (<bold>a</bold>) or two-way ANOVA with Tukey’s multiple comparisons test (<bold>b–e</bold>). Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Loss of <italic>Ifng</italic> gene expression attenuates the proinflammatory phenotype of PHD2<sup>ΔTreg</sup> mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig5-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig5-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Concomitant loss of HIF2α, but not HIF1α, expression partially corrects the proinflammatory phenotype of PHD2<sup>ΔTreg</sup> mice</title><p>Based on the notion that HIF1α and HIF2α represent well-described targets of PHD2, we established a series of conditional KOs mouse strains to identify the molecular pathway responsible for the decreased functional activity of PHD2-deficient Tregs at steady state (<xref ref-type="fig" rid="fig6">Figure 6</xref>; see <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> for strain validation). Treg-selective deletion of HIF1α and HIF2α expression alone did not significantly alter colon length (used as a proxy for spontaneous inflammation) nor general T cell immune homeostasis (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). The same observation was made for double HIF1α and HIF2α KOs (data not shown). In marked contrast, combined deletion of PHD2 and HIF2α reversed some of the inflammatory symptoms observed in PHD2<sup>ΔTreg</sup> mice, such as splenomegaly, colon length (<xref ref-type="fig" rid="fig6">Figure 6a and b</xref>), and hematocrit counts (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Treg-specific, PHD2-HIF1α double KOs were virtually indistinguishable from PHD2<sup>ΔTreg</sup> according to these morphological criteria. Noteworthy, however, Treg-specific PHD2-HIF1α double KOs mice were born at sub-Mendelian ratios and displayed a marked weight loss during adult life and reduced viability, indicative of a more pronounced proinflammatory status (data not shown). This mouse strain also displayed a tendency toward increased expansion of Th1-like cells in peripheral lymph nodes (<xref ref-type="fig" rid="fig6">Figure 6e</xref>). PHD2-HIF1α-HIF2α triple KOs and PHD2-HIF2α double KOs displayed a similar phenotype, establishing a predominant role for HIF2α over HIF1α in mediating the effects of PHD2 on the capacity of Treg to regulate immune homeostasis at rest. Similarly, lack of HIF2α expression largely reversed the altered phenotype of conventional T cells induced by loss of Treg-associated PHD2 expression. Indeed, cells from double (PHD2-HIF2α) and triple (PHD2-HIF1α-HIF2α) Treg-specific KOs displayed a near-normal phenotype (based on CD62L and CD44 expression) and propensity to secrete IFN-γ (<xref ref-type="fig" rid="fig6">Figure 6c–e</xref>). Finally, loss of Treg-associated expression of HIF2α also reversed the expansion of Treg numbers (<xref ref-type="fig" rid="fig6">Figure 6f</xref>) and restored Foxp3 protein expression to near-control levels (<xref ref-type="fig" rid="fig6">Figure 6g</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Concomitant loss of HIF2α but not HIF1α expression attenuates the proinflammatory phenotype of PHD2<sup>ΔTreg</sup> mice.</title><p>(<bold>a</bold>) Representative gross autopsy of spleens and colon length summarized in (<bold>b</bold>) of Foxp3<sup>cre</sup>, PHD2<sup>ΔTreg</sup>, PHD2-HIF1α<sup>ΔTreg</sup>, PHD2-HIF2α<sup>ΔTreg</sup>, and PHD2-HIF1α-HIF2α<sup>ΔTreg</sup> (TKO) mice. (<bold>c</bold>) Representative merged (n = 15) t-distributed stochastic neighbor embedding (t-SNE) plot after dimensionality reduction and unsupervised clustering of flow cytometry data from CD4-expressing spleen cells. Relative distributions of CD4<sup>+</sup> lymphocyte subsets are shown as doughnut charts. (<bold>d–g</bold>) Lymphoid cells from spleen, mesenteric (mLN), peripheral (pLN) lymph nodes, or the small intestine lamina propria were collected from Foxp3<sup>cre</sup>, PHD2<sup>ΔTreg</sup>, PHD2-HIF1α<sup>ΔTreg</sup> mice, PHD2-HIF2α<sup>ΔTreg</sup> and PHD2-HIF1α-HIF2α<sup>ΔTreg</sup> (TKO) male and female mice and the relative frequency and phenotype of Foxp3-positive and Foxp3-negative, conventional T lymphocytes determined by flow cytometry. (<bold>d</bold>) Frequency of effector-like (CD44<sup>hi</sup> CD62L<sup>lo</sup>) conventional T lymphocytes in the indicated lymphoid organs. (<bold>e</bold>) Frequency of IFN-γ-producing CD4<sup>+</sup> T cells after in vitro stimulation. (<bold>f</bold>) Frequency of Foxp3-expressing cells among CD4-positive T lymphocytes. (<bold>g</bold>) Ratio of the Foxp3 MFI of PHD2-KO, PHD2-HIF1αKO, PHD2-HIF2αKO, or TKO splenic Tregs to Foxp3<sup>cre</sup> splenic Tregs. Data are representative of at least three independent experiments with n = 15 per groups. Values are expressed as the mean ± SD and were compared by one-way ANOVA with Tukey’s multiple comparisons test (<bold>b, g</bold>) or two-way ANOVA with Tukey’s multiple comparisons test (<bold>d–f</bold>). Only significant differences are indicated as follows: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Concomitant loss of HIF2α but not HIF1α expression attenuates the proinflammatory phenotype of PHD2<sup>ΔTreg</sup> mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Treg-selective HIF1α or HIF2α deficiency does not affect immune homeostasis in naive mice.</title><p>(<bold>a</bold>) Splenic Treg cells were purified by cell sorting from Foxp3<sup>cre</sup> (n = 3), PHD2<sup>ΔTreg</sup> (n = 2), PHD2-HIF1α<sup>ΔTreg</sup> (n = 2), PHD2-HIF2α<sup>ΔTreg</sup> (n = 3), PHD2-HIF1α-HIF2α<sup>ΔTreg</sup> (TKO) (n = 3), HIF1α<sup>ΔTreg</sup> (n = 3), and HIF2α<sup>ΔTreg</sup> (n = 3) male mice and their genotype verified by qPCR on the extracted total RNA fraction. (<bold>b</bold>) Representative gross autopsy findings revealing normal spleen and colon size (summarized in panel <bold>c</bold>) in 12-week-old male and female mice. (<bold>d</bold>) Frequency of CD4<sup>+</sup> Foxp3<sup>-</sup> CD44<sup>hi</sup> CD62L<sup>lo</sup> cells in lymphoid organs. (<bold>e</bold>) Frequency of CD4<sup>+</sup> lymphocytes producing IFN-γ upon in vitro stimulation. (<bold>f</bold>) Frequency of Foxp3<sup>+</sup> cells in the indicated lymphoid organs. (<bold>g</bold>) Ratio of the Foxp3 MFI of HIF1αKO or HIF2αKO splenic Tregs to Foxp3<sup>cre</sup> splenic Tregs. Data are representative of three independent experiments with n = 10. Values are presented as the mean ± SD and were compared by one-way ANOVA with Tukey’s multiple comparisons test (<bold>c, g</bold>) or two-way ANOVA with Tukey’s multiple comparisons test (<bold>d–f</bold>). No statistical differences were found between groups.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Treg-selective HIF1α or HIF2α deficiency does not affect immune homeostasis in naive mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig6-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig6-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Transcriptomic analysis identifies cell survival, response to chemokines, and STAT1-mediated signaling as target pathways of the PHD2-HIF2α axis in Tregs</title><p>Collectively, the previous observations suggest that the PHD2-HIF2α regulatory axis confers to Tregs the capacity to control the spontaneous, type 1-like, activity of conventional T cells. To identify PHD2-dependent signaling pathways operating in Tregs, splenic Foxp3-expressing cells were purified from all mouse strains described in this article and their transcriptome analyzed following bulk RNA-seq. A set of 532 genes were found differentially expressed between WT and PHD2-deficient Tregs (<xref ref-type="fig" rid="fig7">Figure 7</xref>) (a summary list of upregulated and downregulated pathways in PHD2<sup>ΔTreg</sup> mice vs. Foxp3<sup>cre</sup> mice is provided in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Differential gene expression analysis between all mouse strains studied identified 1868 genes differentially expressed between groups. An unsupervised clustering of the differentially expressed genes led to the identification of 20 clusters, as shown in <xref ref-type="fig" rid="fig7">Figure 7a</xref>. To identify the gene clusters that were specifically involved in the immune homeostatic control of naive mice, the RNA-seq data were filtered and grouped by k-means clustering. We next searched for sets of genes whose expression best correlated with an arbitrary inflammatory index, established based on previously described findings (mostly colon length, splenomegaly, and spontaneous conventional T cell activation status) and summarized in <xref ref-type="fig" rid="fig7">Figure 7b</xref>. In particular, while concomitant deletion of HIF1α expression worsened the inflammatory status of PHD2<sup>ΔTreg</sup> mice, loss of HIF2α expression mitigated most inflammatory-related parameters at rest. We therefore clustered genes according to a ‘gradient of disease severity’ and grouped them in sets of gene whose expression decreased (cluster 10, <xref ref-type="fig" rid="fig7">Figure 7c</xref>) or increased (cluster 11, <xref ref-type="fig" rid="fig7">Figure 7d</xref>) accordingly. Gene Ontology analysis of these clustered gene sets revealed the following. Reduced expression of cell death-related and gain of survival-associated gene expression correlated with the increased frequency of Tregs in the corresponding mouse strains (<xref ref-type="fig" rid="fig7">Figure 7c and d</xref>). Not surprisingly, the expression of genes associated with anti-inflammatory responses was gradually lost according to the same severity gradient. Finally, genes, associated with T cell migration, including several chemokine receptors, also displayed an ordered loss of expression along the same gradient (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). For comparison purposes, genes whose expression was restored to control levels upon combined deletion of PHD2 and HIF1α were also examined. As expected from previously published findings, these HIF1α-dependent biological pathways included glycolysis and angiogenesis (<xref ref-type="fig" rid="fig7">Figure 7e</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Anti-inflammatory response, response to chemokines, and cell survival pathways represent targets of the PHD2-HIF2α axis in Tregs.</title><p>Splenic Treg cells were purified by cell sorting from Foxp3<sup>cre</sup> (n = 3), PHD2<sup>ΔTreg</sup> (n = 2), PHD2-HIF1α<sup>ΔTreg</sup> (n = 2), PHD2-HIF2α<sup>ΔTreg</sup> (n = 3), and PHD2-HIF1α-HIF2α<sup>ΔTreg</sup> (TKO) (n = 3) male mice, and total RNA was extracted and sequenced by RNA-sequencing (Illumina). (<bold>a</bold>) Heatmap of genes differentially expressed. Values are represented as log<sub>2</sub> fold change (FC) obtained from median of each gene and are plotted in red-blue color scale with red indicating increased expression and blue indicating decreased expression. Hierarchical clustering of genes (k-means clustering) shows 20 clusters. (<bold>b</bold>) Classification of mouse strains according to their spontaneous inflammation severity. (<bold>c</bold>) Heatmap of genes downregulated when PHD2 and PHD2-HIF1α are deleted and whose expression is restored to a control level (close to Foxp3<sup>cre</sup> Treg) following deletion of HIF2α (cluster 10, 181 genes). (<bold>d</bold>) Heatmap of genes upregulated when PHD2 and PHD2-HIF1α are deleted and whose expression is restored to a control level following deletion of HIF2α (cluster 11, 66 genes). (<bold>e</bold>) Heatmap of genes upregulated when PHD2 and PHD2-HIF2α are deleted and whose expression is restored to a control level following deletion of HIF1α (cluster 3, 98 genes). Cluster 3, 10, and 11 were subjected to functional annotations and regulatory network analysis in the Ingenuity Pathway Analysis (IPA) software. Data were analyzed using DESeq2, a gene is differentially expressed when log<sub>2</sub>FC &gt; 0.5 and false discovery rate (FDR) &lt; 0.05.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Anti-inflammatory response, response to chemokines, and cell survival pathways represent targets of the PHD2-HIF2α axis in Tregs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Signaling pathways affected by loss of PHD2 expression in Treg.</title><p>(<bold>a</bold>) Top: significantly downregulated pathways in PHD2-deficient Tregs compared to Tregs from Foxp3<sup>cre</sup> mice. (<bold>b</bold>) Top: significantly upregulated pathways in PHD2-deficient Tregs compared to Tregs from Foxp3<sup>cre</sup> mice. Affected pathways were determined by over-representation analysis (ORA analysis) in R program after DESeq2 analysis. Dot color and size represent respectively false discovery rate (FDR) and the number of genes affected in a given pathway.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Signaling pathways affected by loss of PHD2 expression in Treg.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig7-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Ingenuity Pathway Analysis (IPA) was performed in order to identify possible upstream regulators affecting expression of downstream genes identified in clusters 10 and 11. This analysis led to the identification of STAT1 as a putative upstream transcription factor regulating the expression of a set of genes whose expression was altered in PHD2-deficient Tregs (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). Since <italic>Stat1</italic> mRNA expression was not altered by PHD2 invalidation (as revealed by RNA-seq analysis), we tested the capacity of STAT1 to undergo phosphorylation in response to IFN-γ. This set of experiments led to the identification of a defective, accumulation of phopho-STAT1 in PHD2-deficient Tregs (<xref ref-type="fig" rid="fig8">Figure 8b and c</xref>), while the levels of total STAT1 protein appeared unaffected (<xref ref-type="fig" rid="fig8">Figure 8d</xref>). Noteworthy, concomitant deletion of HIF2α restored a near-control response to IFN-γ in PHD2-deficient Tregs (<xref ref-type="fig" rid="fig8">Figure 8b–d</xref>). In keeping with the observed proinflammatory phenotype associated with these mouse strains, conventional T cells from PHD2<sup>ΔTreg</sup> mice displayed an augmented response to IFN-γ (as judged by pSTAT1 accumulation), partially reversed in mice bearing Tregs lacking both PHD2 and HIF2α expression (<xref ref-type="fig" rid="fig8">Figure 8b</xref>, left panel). Finally, the proportion of Tregs expressing CXCR3, a well-described STAT1-dependent chemokine receptor (<xref ref-type="bibr" rid="bib26">Hall et al., 2012</xref>), was reduced in a HIF2α-dependent manner in PHD2-deficient Tregs (<xref ref-type="fig" rid="fig8">Figure 8e</xref>), further strengthening the conclusion that PHD2 expression controls the response of Tregs to IFN-γ.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Identification of STAT1-mediated signaling as a target of the PHD2-HIF2α axis in Tregs.</title><p>(<bold>a</bold>) Upregulated and downregulated genes (clusters 10 and 11 in <xref ref-type="fig" rid="fig6">Figure 6c and d</xref>) were imported into the Ingenuity Pathway Analysis (IPA) software and were subjected to Upstream Regulator Analysis (URA) prediction algorithms. STAT1 was predicted as an upstream regulator of downregulated genes with a p-value=3 × 10<sup>–12</sup>. Phosphorylated form of STAT1 (pSTAT1 [Tyr701]) was assessed by flow cytometry after brief in vitro stimulation (30 min) of splenic CD4<sup>+</sup> T lymphocytes with recombinant IFN-γ. (<bold>b</bold>) Representative histogram of pSTAT1 MFI for conventional CD4<sup>+</sup> T cells (Tconv) and Treg cells of Foxp3<sup>cre</sup>, PHD2<sup>ΔTreg</sup>, and PHD2-HIF2α<sup>ΔTreg</sup> male mice. Mean value expression (represented by MFI) of (<bold>c</bold>) pSTAT1 or (<bold>d</bold>) STAT1 total protein by splenic Treg of Foxp3<sup>cre</sup>, PHD2<sup>ΔTreg</sup>, and PHD2-HIF2α<sup>ΔTreg</sup> mice. (<bold>e</bold>) Frequency of Treg cells expressing the CXCR3 receptor. Data are representative of three independent experiments with n = 9 (<bold>b–d</bold>) or n = 12 (<bold>e</bold>) per groups. Values are presented as the mean ± SD and were compared by one-way ANOVA with Tukey’s multiple comparisons. Only significant differences are indicated as follows: **p&lt;0.01, ***p&lt;0.001.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Identification of STAT1-mediated signaling as a target of the PHD2-HIF2α axis in Tregs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70555-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Gating strategy for identification of YFP<sup>+</sup> cells.</title><p>Representative flow cytometry dot plots displaying the gating strategy for the identification of YFP-positive populations in the (<bold>a</bold>) spleen, (<bold>b</bold>) mesenteric lymph node (mLN), (<bold>c</bold>) thymus, and (<bold>d</bold>) liver. Although the majority of YFP-expressing cells also expressed Foxp3, a minor population (from 1% to 3% depending on the organ considered) of YFP cells lacked expression of both CD45 and Foxp3, suggesting a possible expression of the Cre-recombinase in nonhematopoietic cells in PHD2<sup>ΔTreg</sup> mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70555-fig8-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This study highlights the important role of the prolyl-hydroxylase PHD2 in the regulation of Treg development and function. Deletion of PHD2 in developing Tregs led to the accumulation of the subset of Treg precursor characterized by low expression of Foxp3 at the expenses of the mature Foxp3<sup>+</sup>CD25<sup>+</sup> Treg population (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). PHD2-deficient Tregs were nevertheless found in increased numbers in vivo at steady state (<xref ref-type="fig" rid="fig2">Figure 2a</xref>), albeit with an altered phenotype. In particular, the expression of molecules known to be associated with optimal suppressive activity (such as Foxp3, ICOS ,and CD25) (<xref ref-type="bibr" rid="bib39">Lu et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Fontenot et al., 2003</xref>; <xref ref-type="bibr" rid="bib52">Redpath et al., 2013</xref>) was marginally decreased, while the expression of PD-1, a marker associated with altered functional activity of many immune cells including Tregs (<xref ref-type="bibr" rid="bib38">Lowther et al., 2016</xref>; <xref ref-type="bibr" rid="bib62">Tan et al., 2021</xref>), was augmented. Of note, other molecules known to play an important role in Treg function were expressed at optimal levels (cf. CTLA4 and IL-10).</p><p>Although we have not specifically addressed the role of PHD2 in thymic vs. peripherally induced Tregs, it is noteworthy that lack of PHD2 expression altered Treg thymic development without any major effect on the generation of iTreg in vitro, suggesting a more pronounced role of PHD2 on thymic vs. peripherally generated Tregs, although this conclusion should be strengthened by additional studies.</p><p>Mice selectively lacking PHD2 expression in Treg displayed a proinflammatory phenotype (with early manifestations of gastrointestinal tract inflammation) associated to an elevated hematocrit, enhanced vascular permeability, and an altered homeostatic profile of splenic conventional T cells. In marked contrast to WT Tregs, PHD2-deficient Tregs express relatively high levels of <italic>Vegfa</italic> transcripts (as established from RNA-seq analysis), a factor known to both increase vascular permeability (<xref ref-type="bibr" rid="bib5">Bates, 2010</xref>) and induce erythropoietin (Epo) production from perivascular stromal cells in several organs (<xref ref-type="bibr" rid="bib23">Greenwald et al., 2019</xref>). Alternatively, since the expression of the YFP-Cre allele was found in a minor proportion of CD45-negative cells in all organs examined (see <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). PHD2 deletion could result in elevated expression of Epo from a nonhematopoietic source. In any event, analysis of several organs (including spleen, liver, and kidney) from PHD2<sup>ΔTreg</sup> mice failed to reveal any increase in <italic>Epo</italic> mRNA accumulation (our own unpublished observations), and further studies will therefore be required to identify the mechanism underlying the observed hematological alterations in PHD2<sup>ΔTreg</sup> mice. Several observations, however, strongly indicate that the major proinflammatory phenotype observed in these mice were due to the specific impairment in Treg function consequent to the loss of PHD2 activity. Despite previous reports describing the stochastic activity of the <italic>Foxp3</italic>-Cre-YFP allele in non-Tregs leading to the recombination of some, but not all, alleles (<xref ref-type="bibr" rid="bib22">Franckaert et al., 2015</xref>), we consistently found a control-level expression of PHD2 in all conventional T cell subsets tested (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Secondly, co-transfer of highly purified Tregs with WT naive CD4<sup>+</sup> conventional target cells clearly demonstrated an intrinsic role of PHD2 in regulating Treg function. Finally, and this will be discussed further below, mice bearing double PHD2-HIF2α-deficient Tregs recover a near-control phenotype, further excluding a major influence of the genetic background on the observed phenotype. Our observations confirm and further extend the observations from a study published during the completion of our work (<xref ref-type="bibr" rid="bib73">Yamamoto et al., 2019</xref>), indicating a specific nonredundant role for PHD2 in controlling Treg activity in vivo.</p><p>Based on the notion that hypoxia-induced factors represent major substrates of PHD2, we generated a series of mouse strains to evaluate the relative role of HIF1α and HIF2α in regulating Treg phenotype and function. The combined loss of PHD2 and HIF2α, but not HIF1α, corrected some, but not all, abnormalities found in the PHD2<sup>ΔTreg</sup> mouse strain. To uncover the mechanism whereby the PHD2-HIF2α axis regulates the capacity of Tregs to exert a homeostatic control over conventional T cells, a large transcriptomic analysis was undertaken. To be able to isolate genes specifically involved in the control of Treg activity in naive animals, we took advantage of the graded proinflammatory status of the mouse strain generated (based on colon length and spontaneous activation of Tconv cells, see <xref ref-type="fig" rid="fig6">Figure 6</xref>) to identify the gene clusters whose expression correlated with Treg-mediated immune homeostasis. This analysis led us to identify the important pathways providing mechanistic insights into the role of the PHD2-HIF2α axis in Treg biology. In particular, loss of PHD2 led to an altered expression of genes coding for chemokine receptors and adhesion molecules, suggesting a potential role of this oxygen sensor in chemotaxis and traffic. This conclusion is of particular interest in light of two observations described in this study. As previously discussed, PHD2<sup>ΔTreg</sup> mice displayed a selective expansion of Th1-prone effectors in all lymphoid organs examined (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Accordingly, ubiquitous loss of IFN-γ expression strongly attenuated the pro-inflammatory phenotype of mice with PHD2-deficient Tregs (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>), thus suggesting a specific role for PHD2 in endowing Tregs to control Th1-like immune responses in vivo. Secondly, the IPA conducted on the transcriptomic data led to the identification of STAT1 as a potential common regulator of many genes whose expression was under the control of the PHD2-HIF2α axis, including in particular CXCR3 (<xref ref-type="bibr" rid="bib26">Hall et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Koch et al., 2009</xref>). Based on the well-described role for Treg-expressed CXCR3 in modulating Th1-like responses in vivo (<xref ref-type="bibr" rid="bib35">Levine et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Littringer et al., 2018</xref>) and the reduced expression of this chemokine receptor described in this study (<xref ref-type="fig" rid="fig8">Figure 8e</xref>), it is tempting to speculate that the reduced capacity of PHD2-deficient Tregs to control Th1 responses is a consequence of an altered STAT1 signaling pathway, leading to reduced CXCR3 expression. It is noteworthy that response to CXCR3 ligands has been recently shown to determine the precise positioning of effector and memory CD8 cells in peripheral lymph nodes (<xref ref-type="bibr" rid="bib19">Duckworth et al., 2021</xref>). Further studies would be required to identify the precise mechanism at work since the expression of many potential chemokine receptors (including CXCR4, known to exert inhibitory function over other chemokine receptors; <xref ref-type="bibr" rid="bib7">Biasci et al., 2020</xref>) and adhesion molecules (such as Ly6a or CD44) appears under the control of the PHD2-HIF2α axis in Tregs. Whether altered positioning of Tregs within lymphoid organs represents an important factor contributing to the proinflammatory phenotype of PHD2<sup>ΔTreg</sup> mice remains, however, to be thoroughly examined. Similarly, the potential mechanistic link between HIF2α and STAT1 activation remains to be firmly established by further investigations.</p><p>Collectively, the observations reported in this study demonstrate a nonredundant role for PHD2 in controlling survival, phenotype, and the capacity of Tregs to control Th1-like responses. These biological responses appear under the control of HIF2α and are largely independent of HIF1α-regulated metabolic pathways. Although the role of the PHD2-HIF2α axis has been previously highlighted by Yamamoto and colleagues using an alternative shRNA-based approach (<xref ref-type="bibr" rid="bib73">Yamamoto et al., 2019</xref>), our observations do not fully concur with the previous study on two grounds. First, in contrast to PHD2 knockdown (PHD2-KD) cells, PHD2-genetically deficient Tregs retained full suppressive capacities in vitro. Secondly, no sign of reversal to an effector state was found in PHD2-KO regulatory T cells, whereas downregulation of PHD2 expression led to an increased expression of T-bet, GATA-3, and TNFα. Notably, PHD2-KD Tregs were able to induce skin-graft rejection in the absence of bona fide effector cells, suggesting a possible acquisition of effector function by these cells. Although these observations are compatible with a possible gene-dosage effect of PHD2 on Treg biology, further studies are needed to identify the mechanism at work in these two experimental models.</p><p>In any events, both studies concur in identifying a possible deleterious role of HIF2α overactivation in the control of regulatory T cell function. These findings appear at odds with a recent publication by Tzu-Sheng Hsu and colleagues in which deletion of HIF2α, but not HIF1α, expression was found to negatively affect Treg function (<xref ref-type="bibr" rid="bib28">Hsu et al., 2020</xref>). Of note, concomitant deletion of both HIF1α and HIF2α restored the suppressive activity of Tregs (<xref ref-type="bibr" rid="bib28">Hsu et al., 2020</xref>). An elegant hypothesis, put forward by these authors, may help reconcile some of these apparently contradictory observations. Most experimental evidence concurs with a dual role of HIF1α in Treg differentiation and stability. In the setting of suboptimal Treg-inducing conditions, HIF1α may promote adequate expression of Foxp3 by differentiating Tregs. Once the Treg phenotype has been fully acquired, HIF1α protein expression is reduced following interaction with Foxp3 (<xref ref-type="bibr" rid="bib11">Clambey et al., 2012</xref>), thus explaining the relative lack of influence of HIF1α on differentiated Tregs. As a consequence, HIF1α-KO Tregs retain full suppressive activity (<xref ref-type="bibr" rid="bib28">Hsu et al., 2020</xref>). The interaction between HIF1α and Foxp3 can, however, also lead to Foxp3 protein degradation, and thus Treg instability. Therefore, forced stabilization of HIF1α (such as observed in triple PHD KOs [<xref ref-type="bibr" rid="bib13">Clever et al., 2016</xref>] or pVHL-deficient Tregs [<xref ref-type="bibr" rid="bib33">Lee et al., 2015a</xref>]) leads to loss of Foxp3 expression and Treg identity and acquisition of proinflammatory functions. Inflammation observed in these mouse strains can be largely attributed to the proinflammatory influence of ex-Tregs. As discussed for HIF1α, HIF2α also appears to regulate Treg stability, albeit in a different direction. Despite a normal phenotype at rest, mice displaying HIF2α-deficient Tregs were largely defective in suppressing inflammation in the gut and lungs (<xref ref-type="bibr" rid="bib28">Hsu et al., 2020</xref>). This proinflammatory phenotype was largely explained by the HIF1α-dependent reprogramming of HIF2α-deficient Tregs into IL-17-secreting cells. Collectively, the available literature points to a central role for HIF1α in determining Treg stability and function in vivo. Depending on the biological pathway leading to its increased expression and/or protein stabilization, HIF1α promotes the differentiation of Tregs into IFN-γ (in triple PHD KOs or pVHL-deficient Tregs) or IL-17 (in HIF2α-deficient Tregs) secreting cells. Although the mechanism underlying the acquisition of Th1 vs. Th17-like profiles in these models remains to be established, the induction of a glycolytic metabolism is probably instrumental in mediating Treg instability (<xref ref-type="bibr" rid="bib60">Shi and Chi, 2019</xref>).</p><p>In the present study, loss of HIF1α expression did not revert the phenotype of PHD2-HIF2α-deficient Tregs, despite re-establishing a control-like expression of pro-glycolytic genes (<xref ref-type="fig" rid="fig7">Figure 7e</xref>). Accordingly, PHD2-deficient Tregs did not acquire the capacity to produce proinflammatory cytokines (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) nor displayed any significant loss of Foxp3 expression upon in vitro culture (<xref ref-type="fig" rid="fig2">Figure 2k and l</xref>) or in vivo transfer (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). Thus, the available evidence suggests that in PHD2-sufficient cells HIF2α allows adequate Treg function by negating the influence of HIF1α on Foxp3-expression, while overactivation of HIF2α activity secondary to the loss of PHD2 expression leads to altered Treg phenotype, most probably via a STAT1-dependent pathway.</p><p>Considering the specific role of PHD2, it is worth mentioning that both the transcriptomic data and our own unpublished observations (indicating an increased sensitivity of triple PHD2-HIF1α-HIF2α Tregs-specific KO mice to chemical induced colitis) suggest that while the capacity of Tregs to control tissue homeostasis in the naive state is under the predominant control of the PHD2-HIF2α axis, other non-HIF PHD2-substrates (<xref ref-type="bibr" rid="bib46">Meneses and Wielockx, 2016</xref>; <xref ref-type="bibr" rid="bib47">Mikhaylova et al., 2008</xref>; <xref ref-type="bibr" rid="bib10">Chan et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Romero-Ruiz et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Huo et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Xie et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Lee et al., 2015b</xref>; <xref ref-type="bibr" rid="bib24">Guo et al., 2016</xref>) probably play an important role in Treg biology under strong inflammatory settings. Finally, this study suggests that some caution should be exerted in the administration of PHD inhibitors presently considered for the treatment of renal anemia (<xref ref-type="bibr" rid="bib25">Gupta and Wish, 2017</xref>), inflammatory bowel diseases (<xref ref-type="bibr" rid="bib41">Marks et al., 2015</xref>), as well as Parkinson’s disease (<xref ref-type="bibr" rid="bib36">Li et al., 2018</xref>) as these compounds may display some proinflammatory effects via the alteration of Treg phenotype and function in vivo.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:5658455">MGI:5658455</ext-link></td><td align="left" valign="bottom">Horst, The Netherlands</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Egln1</italic><sup>f/f</sup></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_NM-CKO-2100497">IMSR_NM-CKO-2100497</ext-link></td><td align="left" valign="bottom">P. Carmeliet (VIB-KULeuven)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Foxp3</italic>-Cre-YFP</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18387831/">18387831</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:016959">IMSR_JAX:016959</ext-link></td><td align="left" valign="bottom">A. Liston (KULeuven)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Hif1a</italic><sup>f/f</sup> (Hif1atm3Rsjo/J)</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:007561">IMSR_JAX:007561</ext-link></td><td align="left" valign="bottom">F. Bureau (Liege University)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Epas</italic><sup>f/f</sup> (Epas1tm1Mcs/J)</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:008407">IMSR_JAX:008407</ext-link></td><td align="left" valign="bottom">J.A. Lopez (Madrid University)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Ifng</italic><sup>-/-</sup></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_CARD:178">IMSR_CARD:178</ext-link></td><td align="left" valign="bottom">Bar Harbor, ME</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ)</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:002014">IMSR_JAX:002014</ext-link></td><td align="left" valign="bottom">Bar Harbor, ME</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Rag2</italic><sup>-/-</sup></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:008449">IMSR_JAX:008449</ext-link></td><td align="left" valign="bottom">Bar Harbor, ME</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD278 (Icos)-biotin (C398.4A, mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="char" char="hyphen" valign="bottom">13-9949-82</td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD27-PeCy7 (LG.7F9, mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="char" char="hyphen" valign="bottom">25-0271-82</td><td align="char" char="." valign="bottom">(1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Foxp3-FITC (FJK-16s, mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="char" char="hyphen" valign="bottom">71-5775-40</td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse RORγt-PE (B2D, mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="char" char="hyphen" valign="bottom">12-6981-82</td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse T-bet-PE (4B10, mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="char" char="hyphen" valign="bottom">12-5825-82</td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse PD1-PECF594 (J43, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">562523;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2737634">AB_2737634</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CXCR3-APC (CXCR3-173, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">562266;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11153500">AB_11153500</ext-link></td><td align="char" char="." valign="bottom">(3:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD24-PECF594 (M1/69, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">562477;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11151917">AB_11151917</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD25-BB515 (PC61, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">564424;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2738803">AB_2738803</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD44-PECy7 (IM7, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">560569;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1727484">AB_1727484</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD4-A700 (RM4-5, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">557956;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396956">AB_396956</ext-link></td><td align="char" char="." valign="bottom">(3:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD8-A700 (53-6.7, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">557959;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396959">AB_396959</ext-link></td><td align="char" char="." valign="bottom">(3:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD4-PB (RM4-5, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">558107;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_397030">AB_397030</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD62L-A700 (MEL-14, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">560517;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1645210">AB_1645210</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse GATA3-PE (L50-823, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">560074;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1645330">AB_1645330</ext-link></td><td align="char" char="." valign="bottom">(1:10)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse RORγt-PECF594 (Q31-378, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">562684;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2651150">AB_2651150</ext-link></td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse STAT1 (pY701)-A488(4a, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">612596;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_399879">AB_399879</ext-link></td><td align="char" char="." valign="bottom">(1:10)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IFNγ-PE (XMG1.2, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">554412;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395376">AB_395376</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IL-10-APC (JES5-16E3, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">554468;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_398558">AB_398558</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IL-17-PerCP-Cy5.5 (N49-653, mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">560799;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2033981">AB_2033981</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD3 antibody (2c11, mouse monoclonal)</td><td align="left" valign="bottom">BioXCell</td><td align="char" char="ndash" valign="bottom">145-2c11</td><td align="left" valign="bottom">20 μg/mouse</td></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">Streptavidin-PECy7.</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">557598;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10049577">AB_10049577</ext-link></td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">IFN-γ protein</td><td align="left" valign="bottom">PeproTech</td><td align="char" char="ndash" valign="bottom">315-05</td><td align="char" char="." valign="bottom">50 ng/ml</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Evans blue</td><td align="left" valign="bottom">Sigma</td><td align="char" char="hyphen" valign="bottom">314-13-6</td><td align="char" char="." valign="bottom">0.5%</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Brefeldin-A</td><td align="left" valign="bottom">eBioscience</td><td align="char" char="hyphen" valign="bottom">00-4506-51</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dextran sodium sulfate, colitis grade (36,000–50,000 Da)</td><td align="left" valign="bottom">MP Biomedical</td><td align="char" char="." valign="bottom">160110</td><td align="char" char="." valign="bottom">2%</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LIVE/DEAD kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">L10119</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-CD90.2 beads MACS</td><td align="left" valign="bottom">Miltenyi</td><td align="char" char="hyphen" valign="bottom">130-121-278</td><td align="char" char="." valign="bottom">(1:5)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-CD4 beads MACS</td><td align="left" valign="bottom">Miltenyi</td><td align="char" char="hyphen" valign="bottom">130-117-043</td><td align="char" char="." valign="bottom">(1:3)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Egln1 (PHD2)_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGGCTATGTCCGTCACGTTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Egln1 (PHD2)_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TACCTCCACTTACCTTGGCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Egln2 (PHD1)_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCACGTGGACGCAGTAATCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Egln2 (PHD1)_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CGCCATGCACCTTAACATCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Egln3 (PHD3)_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGGCAATGGTGGCTTGCTAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Egln3 (PHD3)_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GACCCCTCCGTGTAACTTGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Hif1a_</italic>F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CATCAGTTGCCACTTCCCCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Hif1a_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGCATCCAGAAGTTTTCTCACAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Epas1 (HIF2a)_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACGGAGGTCTTCTATGAGTTGGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Epas1 (HIF2a)_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTTATCCATTTGCTGGTCGGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ifng_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGCCAAGTTTGAGGTCAACA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ifng_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GAATCAGCAGCGACTCCTTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il12a_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCTCAGTTTGGCCAGGGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il12a_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CAGGTTTCGGGACTGGCTAAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il10_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCTGGGTGAGAAGCTGAAGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il10_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCTCCACTGCCTTGCTCTTA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il17a_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ATCCCTCAAAGCTCAGCGTGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il17a_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGGTCTTCATTGCGGTGGAGAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il1b_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CAAGCTTCCTTGTGCAAGTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il1b_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGGTGGCATTTCACAGTTGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il4_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ATGCACGGAGATGGATGTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il4_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AATATGCGAAGCACCTTGGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il6_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTTCTCTGGGAAATCGTGGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il6_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCAAGTGCATCATCGTTGTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Rpl32_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACATCGGTTATGGGAGCAAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Rpl32_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCCAGCTCCTTGACATTGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Tnfa_F</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCCTCCCTCTCATCAGTTCTA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Tnfa_R</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCTACGACGTGGGCTACAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il12b_</italic>F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ATGTGTCCTCAGAAGCTAACC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il12b_</italic>R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CTAGGATCGGACCCTGCAGGGAAC</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism 6</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom">Version 6.0</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>C57BL/6 mice were purchased from Envigo (Horst, The Netherlands). <italic>Egln1</italic><sup>f/f</sup> mice were provided by P. Carmeliet (VIB-KULeuven, Leuven, Belgium); <italic>Foxp3</italic>-Cre-YFP mice, developed by A. Rudensky (<xref ref-type="bibr" rid="bib54">Rubtsov et al., 2008</xref>), were kindly provided by A. Liston (KULeuven, Leuven, Belgium); Hif1atm3Rsjo/J (<italic>Hif1a</italic><sup>f/f</sup>) mice were kindly provided by F. Bureau (Liege University, Liege, Belgium); Epas1tm1Mcs/J (<italic>Epas</italic><sup>f/f</sup>) mice were provided by J.A. Lopez (Madrid University, Madrid, Spain); <italic>Ifng</italic><sup>-/-</sup>, CD45.1 (B6.SJL-Ptprc<sup>a</sup> Pepc<sup>b</sup>/Boy<sup>J</sup>) and <italic>Rag2</italic><sup>-/-</sup> mice were obtained from The Jackson Laboratory (Bar Harbor, ME). All mice were backcrossed for more than 10 generations into a C57BL/6 background and housed in individually ventilated cages. <italic>Foxp3</italic>-Cre-YFP mice were crossed with <italic>Egln1</italic><sup>f/f</sup>, <italic>Hif1a</italic><sup>f/f</sup>, <italic>Epas</italic><sup>f/f</sup> to produce mice with Treg-specific deletion of PHD2, HIF1α, HIF2α, PHD2-HIF1α, PHD2-HIF2α, or PHD2-HIF1α-HIF2α. Heterozygous <italic>Foxp3</italic><sup>cre/+</sup> <italic>Egnl1</italic><sup>fl/fl</sup> mice were generated by crossing the <italic>Foxp3</italic>-Cre-YFP mice with <italic>Egln1</italic><sup>f/f</sup> mice. All mice were used between 8 and 14 weeks of age. PHD2-sufficient mice (expressing <italic>Foxp3</italic>-Cre-YFP, or floxed forms of PHD2, HIF1α, and HIF2α-encoding alleles and generated as littermates in our colony) were used as appropriate controls in the early stages of this work. These mice displayed a phenotype indistinguishable from WT mice and were therefore considered as a single experimental group throughout this study in order to reach statistical significance in all experiments. The experiments were carried out in compliance with the relevant laws and institutional guidelines and were approved by the Université Libre de Bruxelles Institutional Animal Care and Use Committee (protocol number CEBEA-4).</p></sec><sec id="s4-2"><title>Antibodies, intracellular staining, and flow cytometry</title><p>The following monoclonal antibodies were purchased from eBioscience: CD278 (ICOS)-biotin, CD27-PeCy7, Foxp3-FITC, RORγt-PE, T-bet-PE; or from BD Biosciences: PD1-PECF594, CXCR3-APC, CD24-PECF594, CD25-BB515, CD44-PECy7, CD4-A700, CD8-A700, CD4-PB, CD62L-A700, GATA3-PE, RORγt-PECF594, STAT1 (pY701)-A488, IFNγ-PE, IL-10-APC, IL-17-PerCP-Cy5.5, streptavidin-PECy7. Live/dead fixable near-IR stain (Thermo Fisher) was used to exclude dead cells. For transcription factor staining, cells were stained for surface markers, followed by fixation and permeabilization before nuclear factor staining according to the manufacturer’s protocol (Foxp3 staining buffer set from eBioscience). For cytokine staining, cells were stimulated in media containing phorbol 12-myristate 13-acetate (50 ng/ml, Sigma-Aldrich), ionomycin (250 ng/ml, Sigma-Aldrich), and brefeldin-A (1/100, eBioscience) for 3 hr. After stimulation, cells were stained for surface markers, followed by fixation and permeabilization before intracellular staining according to the manufacturer’s protocol (cytokine staining buffer set from BD Biosciences). For phosphorylation staining, cells were stimulated with IFN-γ (50 ng/ml, PeproTech) for 30 min, fixed with formaldehyde, and permeabilized with methanol before staining. Flow cytometric analysis was performed on a Canto II (BD Biosciences) and analyzed using FlowJo software (Tree Star).</p></sec><sec id="s4-3"><title>T cell cultures</title><p>After removal of Peyer’s patches and mesenteric fat, intestinal tissues were washed in Hank’s balanced salt solution (HBSS) 3% fetal calf serum (FCS) and phosphate-buffered saline (PBS), cut in small sections, and incubated in HBSS 3% FCS containing 2.5 mM EDTA and 72.5 µg/ml DTT for 30 min at 37°C with agitation to remove epithelial cells, and then minced and dissociated in RPMI containing liberase (20 µg/ml, Roche) and DNase (400 µg/ml, Roche) at 37°C for 30 min. Leukocytes were collected after a 30% Percoll gradient (GE Healthcare). Lymph nodes and spleens were mechanically disrupted in culture medium. CD4<sup>+</sup> T cells were positively selected from organ cell suspensions by magnetic-activated cell sorting using CD4 beads (MACS, Miltenyi) according to the manufacturer’s protocol and purified as CD4<sup>+</sup> CD44<sup>lo</sup>CD62L<sup>hi</sup>CD25<sup>−</sup> or CD4<sup>+</sup> CD44<sup>lo</sup> CD62L<sup>hi</sup> YFP<sup>−</sup> by fluorescence-activated cell sorting. T cells were cultured at 37°C in RPMI supplemented with 5% heat-inactivated fetal bovine serum (Sigma-Aldrich), 1% nonessential amino acids (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), 500 U/ml penicillin/500 µg/ml streptomycin (Invitrogen), and 50 μM β-mercaptoethanol (Sigma-Aldrich). To generate iTreg cells, cells were cultured in 24-well plates coated with 5 µg/ml anti-CD3 (BioXCell, clone 145-2C11) at 37°C for 72 hr. The culture was supplemented with anti-CD28 (1 µg/ml, BioXCell, clone 37.51), TGF-β (3 ng/ml, eBioscience), and IL-2 (10 ng/ml, PeproTech) for optimal iTreg cell polarization.</p></sec><sec id="s4-4"><title>Treg cell suppression assays</title><sec id="s4-4-1"><title>In vitro assay</title><p>CD4<sup>+</sup> CD44<sup>lo</sup>CD62L<sup>hi</sup> CD25<sup>−</sup> naive T cells were isolated from the spleen of CD45.1<sup>+</sup> mice by cell sorting after positive enrichment for CD4<sup>+</sup> cells using MACS LS columns (Miltenyi) and labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, Thermo Fisher). CD4<sup>+</sup>YFP<sup>+</sup> Treg cells were isolated from the spleen of Foxp3<sup>cre</sup> or PHD2<sup>ΔTreg</sup> mice by cell sorting. Splenocytes from wild-type B6 mice were depleted in T cells (anti-CD90.2 beads, MACS, Miltenyi) using MACS LS columns (Miltenyi) and used as feeder cells. 4 × 10<sup>4</sup> CFSE-labeled naive T cells were cultured for 72 hr with feeder cells (1 × 10<sup>5</sup>) and soluble anti-CD3 (0,5 μg/ml) in the presence or absence of various numbers of Treg cells as indicated.</p></sec><sec id="s4-4-2"><title>In vivo assay</title><p>Rag2<sup>-/-</sup> mice were injected i.v. with a mixture of naive, CFSE-labeled, CD4<sup>+</sup> T cells (CD45.1<sup>+</sup> CD4<sup>+</sup> CD44<sup>lo</sup> CD62L<sup>hi</sup> CD25<sup>−</sup>) (1 × 10<sup>6</sup>) and splenic Treg from Foxp3<sup>cre</sup> or PHD2<sup>ΔTreg</sup> mice (3.3 × 10<sup>5</sup>). Six days after the injection, <italic>Rag2</italic><sup>-/-</sup> mice were sacrificed and CD4<sup>+</sup> T cells proliferation and activation analyzed by flow cytometry.</p></sec></sec><sec id="s4-5"><title>DSS-induced colitis</title><p>Foxp3<sup>cre</sup> or PHD2<sup>ΔTreg</sup> mice were provided with 2% DSS (MP Biomedical, 160110) in tap water for 5 days. On day 5, the DSS-containing water was replaced with normal drinking water and mice were followed during 14 days for body weight, survival, and colitis severity. Colitis severity score was assessed by examining weight loss, feces consistency, and hematochezia (Hemoccult SENSA, Mckesson Medical-Surgical, 625078) as described in <xref ref-type="bibr" rid="bib31">Kim et al., 2012</xref>. Colon samples were washed with PBS and rolled from the distal to proximal end, transected with a needle and secured by bending the end of the needle and fixed in fresh 4% paraformaldehyde (Sigma-Aldrich) overnight and further subjected to routine histological procedures for embedment in paraffin and hematoxylin and eosin (H&amp;E) staining. Tissues were analyzed and scored in a blinded fashion by an independent histopathologist, and representative images were subsequently chosen to illustrate key histological findings.</p></sec><sec id="s4-6"><title>Toxoplasma infection</title><p>ME-49 type II <italic>T. gondii</italic> was kindly provided by Dr De Craeye (Scientific Institute of Public Health, Belgium) and was used for the production of tissue cysts in C57BL/6 mice previously (1–3 months) inoculated with three cysts by gavage. Animals were killed, and the brains were removed. Tissue cysts were counted, and mice were infected by intragastric gavage with 10 cysts. Mice were sacrificed at day 8 after infection.</p></sec><sec id="s4-7"><title>Anti-CD3 mAb-induced enteritis</title><p>Mice were injected i.p. with a CD3-specific antibody (clone 145-2C11, BioXCell 20 μg/mouse) on days 0 and 2 and weighted daily. Mice were sacrificed on day 3 and cytokine production evaluated by qPCR as indicated in the figure legend.</p></sec><sec id="s4-8"><title>Hematological analysis</title><p>Mice blood was obtained from the submandibular vein and collected into heparin-prefilled tubes. Blood samples were analyzed using a Sysmex KX-21 N Automated Hematology Analyzer.</p></sec><sec id="s4-9"><title>Evans blue assay</title><p>Blood vessel permeability was assessed as previously described (<xref ref-type="bibr" rid="bib51">Radu and Chernoff, 2013</xref>). Briefly, 200 μl of a 0.5% sterile solution of Evans blue (Sigma) in PBS was i.v. injected in mice. After 30 min, organs were collected, weighted, and were put in formamide. After 24 hr in a 55°C water bath, absorbance was measured at 600 nm.</p></sec><sec id="s4-10"><title>RT-qPCR</title><p>RNA was extracted using the TRIzol method (Invitrogen) and reverse transcribed with Superscript II reverse transcriptase (Invitrogen) according to the manufacturer’s instructions. Quantitative real-time RT-PCR was performed using the SYBR Green Master mix kit (Thermo Fisher). Primer sequences were as follows:</p><p><italic>Rpl32</italic> (F) <named-content content-type="sequence">ACATCGGTTATGGGAGCAAC</named-content>; <italic>Rpl32</italic> (R) <named-content content-type="sequence">TCCAGCTCCTTGACATTGT</named-content>; <italic>Il1b</italic> (F) <named-content content-type="sequence">CAAGCTTCCTTGTGCAAGTG</named-content>; <italic>Il1b</italic> (R) <named-content content-type="sequence">AGGTGGCATTTCACAGTTGA</named-content>; <italic>Il10</italic> (F) <named-content content-type="sequence">CCTGGGTGAGAAGCTGAAGA</named-content>; <italic>Il10</italic> (R) <named-content content-type="sequence">GCTCCACTGCCTTGCTCTTA</named-content>; <italic>Ifng</italic> (F) <named-content content-type="sequence">TGCCAAGTTTGAGGTCAACA</named-content>; <italic>Ifng</italic> (R) <named-content content-type="sequence">GAATCAGCAGCGACTCCTTT</named-content>; <italic>Il6</italic> (F) <named-content content-type="sequence">GTTCTCTGGGAAATCGTGGA</named-content>; <italic>Il6</italic> (R) <named-content content-type="sequence">GCAAGTGCATCATCGTTGTT</named-content>; <italic>Il17a</italic> (F) <named-content content-type="sequence">ATCCCTCAAAGCTCAGCGTGTC</named-content>; <italic>Il17a</italic> (R) <named-content content-type="sequence">GGGTCTTCATTGCGGTGGAGAG</named-content>; <italic>Il12a</italic> (F) <named-content content-type="sequence">CCTCAGTTTGGCCAGGGTC</named-content>; <italic>Il12a</italic> (R) <named-content content-type="sequence">CAGGTTTCGGGACTGGCTAAG</named-content>; <italic>Il12b</italic> (F) <named-content content-type="sequence">ATGTGTCCTCAGAAGCTAACC</named-content>; <italic>Il12b</italic> (R) <named-content content-type="sequence">CTAGGATCGGACCCTGCAGGGAAC</named-content>; <italic>Tnfa</italic> (F) <named-content content-type="sequence">GCCTCCCTCTCATCAGTTCTA</named-content>; <italic>Tnfa</italic> (R) <named-content content-type="sequence">GCTACGACGTGGGCTACAG</named-content>; <italic>Egln1</italic> (F) <named-content content-type="sequence">AGGCTATGTCCGTCACGTTG</named-content>; <italic>Egln1</italic> (R) <named-content content-type="sequence">TACCTCCACTTACCTTGGCG</named-content>; <italic>Hif1a</italic> (F) <named-content content-type="sequence">CATCAGTTGCCACTTCCCCA</named-content>; <italic>Hif1a</italic> (R) <named-content content-type="sequence">GGCATCCAGAAGTTTTCTCACAC</named-content>; <italic>Epas1</italic> (F) <named-content content-type="sequence">ACGGAGGTCTTCTATGAGTTGGC</named-content>; <italic>Epas1</italic> (R) <named-content content-type="sequence">GTTATCCATTTGCTGGTCGGC</named-content>.</p></sec><sec id="s4-11"><title>RNA-sequencing and analysis</title><p>All RNA-seq analyses were performed using ≥2 biological replicates. Total RNA was prepared from purified splenic Treg cells using the TRIzol method (Invitrogen). 200 ng of total RNA was subsequently used to prepare RNA-seq library by using TruSeq RNA sample prep kit (Illumina) according to the manufacturer’s instructions. Paired-end RNA-sequencing was performed on a NovaSeq 6000 (Illumina) (BRIGHTcore joint facility, ULB-VUB, Brussels, Belgium). Sequenced reads were aligned to the mouse genome (NCBI37/mm9), and uniquely mapped reads were used to calculate gene expression. Data analysis was performed using R program (DESeq2 package). Differentially expressed genes are considered significant when the false discovery rate (FDR or adjusted p-value) &lt; 0.05 and the log<sub>2</sub> fold change (FC) &gt; 0.5. Upstream regulators analysis was performed following IPA. IPA predicts functional regulatory networks from gene expression data and provides a significance score (p-value) for each network according to the fit of the network to the set of genes in the database.</p></sec><sec id="s4-12"><title>Statistical analysis</title><p>All statistical analyses were conducted using GraphPad Prism (GraphPad Software). Statistical difference between two groups was determined by an unpaired, two-tailed Student’s <italic>t</italic>-tests. A one-way or two-way ANOVA was used for multigroup comparisons together with Tukey’s multiple comparisons post hoc tests. Survival significance in DSS-induced colitis was determined by a log-rank Mantel–Cox test. Data is judged to be statistically significant when p-value&lt;0.05. In figures, asterisks denote statistical significance (*p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Software, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, She performed additional experiments and contributed to data analysis, She performed additional experiments and contributed to data analysis</p></fn><fn fn-type="con" id="con4"><p>Methodology</p></fn><fn fn-type="con" id="con5"><p>Methodology, She performed additional experiments and contributed to data analysis, She performed additional experiments and contributed to data analysis</p></fn><fn fn-type="con" id="con6"><p>Methodology</p></fn><fn fn-type="con" id="con7"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Funding acquisition, Project administration, Resources, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Project administration, Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The experiments were performed in compliance with the relevant laws and institutional guidelines and were approved by the Local Ethic Committee. We received specific approval for this study from the Université Libre de Bruxelles Institutional Animal Care and Use Committee (protocol numbers CEBEA-4 and 31).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-70555-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data have been deposited in GEO under accession code GSE184581. Numerical data used to generate the figures have been provided as source data files.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Ajouaou</surname><given-names>Y</given-names></name><name><surname>Azouz</surname><given-names>A</given-names></name><name><surname>Taquin</surname><given-names>A</given-names></name><name><surname>Hussein</surname><given-names>H</given-names></name><name><surname>Andris</surname><given-names>F</given-names></name><name><surname>Moser</surname><given-names>M</given-names></name><name><surname>Goriely</surname><given-names>S</given-names></name><name><surname>Leo</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>The oxygen sensor Prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE184581">GSE184581</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Valérie Acolty, Caroline Abdelaziz, and Véronique Dissy for animal care and technical support. The development of mouse models of toxoplasmosis would not have been possible without the kind assistance of Guillaume Oldenhove. This work was supported by the European Regional Development Fund (ERDF) and the Walloon Region (Wallonia-Biomed portfolio, 411132-957270), a grant from the Fonds Jean Brachet and research credit from the National Fund for Scientific Research, FNRS, Belgium. FA is a Research Associate at the FNRS. YA is recipient of a research fellowship from the FNRS/Télévie. HH has been supported by a Belgian FRIA fellowship.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aandahl</surname><given-names>EM</given-names></name><name><surname>Michaëlsson</surname><given-names>J</given-names></name><name><surname>Moretto</surname><given-names>WJ</given-names></name><name><surname>Hecht</surname><given-names>FM</given-names></name><name><surname>Nixon</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens</article-title><source>Journal of Virology</source><volume>78</volume><fpage>2454</fpage><lpage>2459</lpage><pub-id pub-id-type="doi">10.1128/jvi.78.5.2454-2459.2004</pub-id><pub-id pub-id-type="pmid">14963140</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ast</surname><given-names>T</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Oxygen and mammalian cell culture: are we repeating the experiment of Dr. Ox?</article-title><source>Nature Metabolism</source><volume>1</volume><fpage>858</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1038/s42255-019-0105-0</pub-id><pub-id pub-id-type="pmid">32694740</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baik</surname><given-names>AH</given-names></name><name><surname>Jain</surname><given-names>IH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Turning the Oxygen Dial: Balancing the Highs and Lows</article-title><source>Trends in Cell Biology</source><volume>30</volume><fpage>516</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2020.04.005</pub-id><pub-id pub-id-type="pmid">32386878</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartels</surname><given-names>K</given-names></name><name><surname>Grenz</surname><given-names>A</given-names></name><name><surname>Eltzschig</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hypoxia and inflammation are two sides of the same coin</article-title><source>PNAS</source><volume>110</volume><fpage>18351</fpage><lpage>18352</lpage><pub-id pub-id-type="doi">10.1073/pnas.1318345110</pub-id><pub-id pub-id-type="pmid">24187149</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>DO</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Vascular endothelial growth factors and vascular permeability</article-title><source>Cardiovascular Research</source><volume>87</volume><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq105</pub-id><pub-id pub-id-type="pmid">20400620</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Shoshan</surname><given-names>J</given-names></name><name><surname>Maysel-Auslender</surname><given-names>S</given-names></name><name><surname>Mor</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>G</given-names></name><name><surname>George</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha</article-title><source>European Journal of Immunology</source><volume>38</volume><fpage>2412</fpage><lpage>2418</lpage><pub-id pub-id-type="doi">10.1002/eji.200838318</pub-id><pub-id pub-id-type="pmid">18792019</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biasci</surname><given-names>D</given-names></name><name><surname>Smoragiewicz</surname><given-names>M</given-names></name><name><surname>Connell</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Thaventhiran</surname><given-names>JED</given-names></name><name><surname>Basu</surname><given-names>B</given-names></name><name><surname>Magiera</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>TI</given-names></name><name><surname>Bax</surname><given-names>L</given-names></name><name><surname>Gopinathan</surname><given-names>A</given-names></name><name><surname>Isherwood</surname><given-names>C</given-names></name><name><surname>Gallagher</surname><given-names>FA</given-names></name><name><surname>Pawula</surname><given-names>M</given-names></name><name><surname>Hudecova</surname><given-names>I</given-names></name><name><surname>Gale</surname><given-names>D</given-names></name><name><surname>Rosenfeld</surname><given-names>N</given-names></name><name><surname>Barmpounakis</surname><given-names>P</given-names></name><name><surname>Popa</surname><given-names>EC</given-names></name><name><surname>Brais</surname><given-names>R</given-names></name><name><surname>Godfrey</surname><given-names>E</given-names></name><name><surname>Mir</surname><given-names>F</given-names></name><name><surname>Richards</surname><given-names>FM</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name><name><surname>Janowitz</surname><given-names>T</given-names></name><name><surname>Jodrell</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response</article-title><source>PNAS</source><volume>117</volume><fpage>28960</fpage><lpage>28970</lpage><pub-id pub-id-type="doi">10.1073/pnas.2013644117</pub-id><pub-id pub-id-type="pmid">33127761</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bono</surname><given-names>H</given-names></name><name><surname>Hirota</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Meta-Analysis of Hypoxic Transcriptomes from Public Databases</article-title><source>Biomedicines</source><volume>8</volume><elocation-id>E10</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines8010010</pub-id><pub-id pub-id-type="pmid">31936636</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caridade</surname><given-names>M</given-names></name><name><surname>Graca</surname><given-names>L</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models</article-title><source>Frontiers in Immunology</source><volume>4</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00378</pub-id><pub-id pub-id-type="pmid">24302924</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DA</given-names></name><name><surname>Kawahara</surname><given-names>TLA</given-names></name><name><surname>Sutphin</surname><given-names>PD</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Chi</surname><given-names>J-T</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment</article-title><source>Cancer Cell</source><volume>15</volume><fpage>527</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.04.010</pub-id><pub-id pub-id-type="pmid">19477431</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clambey</surname><given-names>ET</given-names></name><name><surname>McNamee</surname><given-names>EN</given-names></name><name><surname>Westrich</surname><given-names>JA</given-names></name><name><surname>Glover</surname><given-names>LE</given-names></name><name><surname>Campbell</surname><given-names>EL</given-names></name><name><surname>Jedlicka</surname><given-names>P</given-names></name><name><surname>de Zoeten</surname><given-names>EF</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name><name><surname>Stenmark</surname><given-names>KR</given-names></name><name><surname>Colgan</surname><given-names>SP</given-names></name><name><surname>Eltzschig</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa</article-title><source>PNAS</source><volume>109</volume><fpage>E2784</fpage><lpage>E2793</lpage><pub-id pub-id-type="doi">10.1073/pnas.1202366109</pub-id><pub-id pub-id-type="pmid">22988108</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clement</surname><given-names>RL</given-names></name><name><surname>Daccache</surname><given-names>J</given-names></name><name><surname>Mohammed</surname><given-names>MT</given-names></name><name><surname>Diallo</surname><given-names>A</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name><name><surname>Lovitch</surname><given-names>SB</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Sage</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Follicular regulatory T cells control humoral and allergic immunity by restraining early B cell responses</article-title><source>Nature Immunology</source><volume>20</volume><fpage>1360</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0472-4</pub-id><pub-id pub-id-type="pmid">31477921</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clever</surname><given-names>D</given-names></name><name><surname>Roychoudhuri</surname><given-names>R</given-names></name><name><surname>Constantinides</surname><given-names>MG</given-names></name><name><surname>Askenase</surname><given-names>MH</given-names></name><name><surname>Sukumar</surname><given-names>M</given-names></name><name><surname>Klebanoff</surname><given-names>CA</given-names></name><name><surname>Eil</surname><given-names>RL</given-names></name><name><surname>Hickman</surname><given-names>HD</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>JH</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Phan</surname><given-names>AT</given-names></name><name><surname>Goulding</surname><given-names>J</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Goldrath</surname><given-names>AW</given-names></name><name><surname>Belkaid</surname><given-names>Y</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche</article-title><source>Cell</source><volume>166</volume><fpage>1117</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.032</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockman</surname><given-names>ME</given-names></name><name><surname>Lippl</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>Y-M</given-names></name><name><surname>Pegg</surname><given-names>HB</given-names></name><name><surname>Figg</surname><given-names>WD</given-names></name><name><surname>Abboud</surname><given-names>MI</given-names></name><name><surname>Heilig</surname><given-names>R</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Myllyharju</surname><given-names>J</given-names></name><name><surname>Schofield</surname><given-names>CJ</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates</article-title><source>eLife</source><volume>8</volume><elocation-id>e46490</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.46490</pub-id><pub-id pub-id-type="pmid">31500697</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrado</surname><given-names>C</given-names></name><name><surname>Fontana</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hypoxia and HIF Signaling: One Axis with Divergent Effects</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3390/ijms21165611</pub-id><pub-id pub-id-type="pmid">32764403</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>EV</given-names></name><name><surname>Barbi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H-Y</given-names></name><name><surname>Jinasena</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Bordman</surname><given-names>Z</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Yen</surname><given-names>H-R</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Zeller</surname><given-names>K</given-names></name><name><surname>Shimoda</surname><given-names>L</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Dang</surname><given-names>CV</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Pan</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1</article-title><source>Cell</source><volume>146</volume><fpage>772</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.07.033</pub-id><pub-id pub-id-type="pmid">21871655</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez-Villar</surname><given-names>M</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regulatory T cells in autoimmune disease</article-title><source>Nature Immunology</source><volume>19</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0120-4</pub-id><pub-id pub-id-type="pmid">29925983</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downes</surname><given-names>NL</given-names></name><name><surname>Laham-Karam</surname><given-names>N</given-names></name><name><surname>Kaikkonen</surname><given-names>MU</given-names></name><name><surname>Ylä-Herttuala</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Differential but Complementary HIF1α and HIF2α Transcriptional Regulation</article-title><source>Molecular Therapy</source><volume>26</volume><fpage>1735</fpage><lpage>1745</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2018.05.004</pub-id><pub-id pub-id-type="pmid">29843956</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duckworth</surname><given-names>BC</given-names></name><name><surname>Lafouresse</surname><given-names>F</given-names></name><name><surname>Wimmer</surname><given-names>VC</given-names></name><name><surname>Broomfield</surname><given-names>BJ</given-names></name><name><surname>Dalit</surname><given-names>L</given-names></name><name><surname>Alexandre</surname><given-names>YO</given-names></name><name><surname>Sheikh</surname><given-names>AA</given-names></name><name><surname>Qin</surname><given-names>RZ</given-names></name><name><surname>Alvarado</surname><given-names>C</given-names></name><name><surname>Mielke</surname><given-names>LA</given-names></name><name><surname>Pellegrini</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>SN</given-names></name><name><surname>Boudier</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>KL</given-names></name><name><surname>Groom</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Effector and stem-like memory cell fates are imprinted in distinct lymph node niches directed by CXCR3 ligands</article-title><source>Nature Immunology</source><volume>22</volume><fpage>434</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00878-5</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esplugues</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>S</given-names></name><name><surname>Gagliani</surname><given-names>N</given-names></name><name><surname>Hauser</surname><given-names>AE</given-names></name><name><surname>Town</surname><given-names>T</given-names></name><name><surname>Wan</surname><given-names>YY</given-names></name><name><surname>O’Connor</surname><given-names>W</given-names></name><name><surname>Rongvaux</surname><given-names>A</given-names></name><name><surname>Van Rooijen</surname><given-names>N</given-names></name><name><surname>Haberman</surname><given-names>AM</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name><name><surname>Kolls</surname><given-names>JK</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>Herold</surname><given-names>KC</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Control of TH17 cells occurs in the small intestine</article-title><source>Nature</source><volume>475</volume><fpage>514</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/nature10228</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontenot</surname><given-names>JD</given-names></name><name><surname>Gavin</surname><given-names>MA</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Foxp3 programs the development and function of CD4+CD25+ regulatory T cells</article-title><source>Nature Immunology</source><volume>4</volume><fpage>330</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/ni904</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franckaert</surname><given-names>D</given-names></name><name><surname>Dooley</surname><given-names>J</given-names></name><name><surname>Roos</surname><given-names>E</given-names></name><name><surname>Floess</surname><given-names>S</given-names></name><name><surname>Huehn</surname><given-names>J</given-names></name><name><surname>Luche</surname><given-names>H</given-names></name><name><surname>Fehling</surname><given-names>HJ</given-names></name><name><surname>Liston</surname><given-names>A</given-names></name><name><surname>Linterman</surname><given-names>MA</given-names></name><name><surname>Schlenner</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Promiscuous Foxp3-cre activity reveals a differential requirement for CD28 in Foxp3+ Promiscuous Foxp3-cre activity reveals a differential requirement for CD28 in Foxp3- Promiscuous Foxp3-cre activity reveals a differential requirement for CD28 in Foxp3</article-title><source>Immunology and Cell Biology</source><volume>93</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/icb.2014.108</pub-id><pub-id pub-id-type="pmid">25533288</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwald</surname><given-names>AC</given-names></name><name><surname>Licht</surname><given-names>T</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Oladipupo</surname><given-names>SS</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Grunewald</surname><given-names>M</given-names></name><name><surname>Keshet</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>215</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1084/jem.20180752</pub-id><pub-id pub-id-type="pmid">30545903</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Chakraborty</surname><given-names>AA</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Gan</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Inuzuka</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Novak</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>JQ</given-names></name><name><surname>Toker</surname><given-names>A</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names><suffix>Jr</suffix></name><name><surname>Wei</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner</article-title><source>Science (New York, N.Y.)</source><volume>353</volume><fpage>929</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1126/science.aad5755</pub-id><pub-id pub-id-type="pmid">27563096</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Wish</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD</article-title><source>American Journal of Kidney Diseases</source><volume>69</volume><fpage>815</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.12.011</pub-id><pub-id pub-id-type="pmid">28242135</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>AO</given-names></name><name><surname>Beiting</surname><given-names>DP</given-names></name><name><surname>Tato</surname><given-names>C</given-names></name><name><surname>John</surname><given-names>B</given-names></name><name><surname>Oldenhove</surname><given-names>G</given-names></name><name><surname>Lombana</surname><given-names>CG</given-names></name><name><surname>Pritchard</surname><given-names>GH</given-names></name><name><surname>Silver</surname><given-names>JS</given-names></name><name><surname>Bouladoux</surname><given-names>N</given-names></name><name><surname>Stumhofer</surname><given-names>JS</given-names></name><name><surname>Harris</surname><given-names>TH</given-names></name><name><surname>Grainger</surname><given-names>J</given-names></name><name><surname>Wojno</surname><given-names>EDT</given-names></name><name><surname>Wagage</surname><given-names>S</given-names></name><name><surname>Roos</surname><given-names>DS</given-names></name><name><surname>Scott</surname><given-names>P</given-names></name><name><surname>Turka</surname><given-names>LA</given-names></name><name><surname>Cherry</surname><given-names>S</given-names></name><name><surname>Reiner</surname><given-names>SL</given-names></name><name><surname>Cua</surname><given-names>D</given-names></name><name><surname>Belkaid</surname><given-names>Y</given-names></name><name><surname>Elloso</surname><given-names>MM</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology</article-title><source>Immunity</source><volume>37</volume><fpage>511</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.06.014</pub-id><pub-id pub-id-type="pmid">22981537</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirota</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Basic Biology of Hypoxic Responses Mediated by the Transcription Factor HIFs and its Implication for Medicine</article-title><source>Biomedicines</source><volume>8</volume><elocation-id>E32</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines8020032</pub-id><pub-id pub-id-type="pmid">32069878</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>T-S</given-names></name><name><surname>Lin</surname><given-names>Y-L</given-names></name><name><surname>Wang</surname><given-names>Y-A</given-names></name><name><surname>Mo</surname><given-names>S-T</given-names></name><name><surname>Chi</surname><given-names>P-Y</given-names></name><name><surname>Lai</surname><given-names>AC-Y</given-names></name><name><surname>Pan</surname><given-names>H-Y</given-names></name><name><surname>Chang</surname><given-names>Y-J</given-names></name><name><surname>Lai</surname><given-names>M-Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HIF-2α is indispensable for regulatory T cell function</article-title><source>Nature Communications</source><volume>11</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/s41467-020-18731-y</pub-id><pub-id pub-id-type="pmid">33024109</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>CJ</given-names></name><name><surname>Sataur</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha</article-title><source>Molecular Biology of the Cell</source><volume>18</volume><fpage>4528</fpage><lpage>4542</lpage><pub-id pub-id-type="doi">10.1091/mbc.e06-05-0419</pub-id><pub-id pub-id-type="pmid">17804822</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>J-C</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Z-N</given-names></name><name><surname>Xu</surname><given-names>X-R</given-names></name><name><surname>Li</surname><given-names>C-M</given-names></name><name><surname>Qi</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Prolyl hydroxylase domain protein 2 regulates the intracellular cyclic AMP level in cardiomyocytes through its interaction with phosphodiesterase 4D</article-title><source>Biochemical and Biophysical Research Communications</source><volume>427</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.09.005</pub-id><pub-id pub-id-type="pmid">22975349</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Shajib</surname><given-names>MS</given-names></name><name><surname>Manocha</surname><given-names>MM</given-names></name><name><surname>Khan</surname><given-names>WI</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Investigating intestinal inflammation in DSS-induced model of IBD</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.3791/3678</pub-id><pub-id pub-id-type="pmid">22331082</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>MA</given-names></name><name><surname>Tucker-Heard</surname><given-names>G</given-names></name><name><surname>Perdue</surname><given-names>NR</given-names></name><name><surname>Killebrew</surname><given-names>JR</given-names></name><name><surname>Urdahl</surname><given-names>KB</given-names></name><name><surname>Campbell</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation</article-title><source>Nature Immunology</source><volume>10</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/ni.1731</pub-id><pub-id pub-id-type="pmid">19412181</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Elly</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity</article-title><source>Immunity</source><volume>42</volume><fpage>1062</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.05.016</pub-id><pub-id pub-id-type="pmid">26084024</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DC</given-names></name><name><surname>Sohn</surname><given-names>HA</given-names></name><name><surname>Park</surname><given-names>ZY</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Jang</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>SJ</given-names></name><name><surname>Hong</surname><given-names>YK</given-names></name><name><surname>Noh</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Bae</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>DM</given-names></name><name><surname>Chung</surname><given-names>SJ</given-names></name><name><surname>Yoo</surname><given-names>HS</given-names></name><name><surname>Yu</surname><given-names>DY</given-names></name><name><surname>Park</surname><given-names>KC</given-names></name><name><surname>Yeom</surname><given-names>YI</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>A lactate-induced response to hypoxia</article-title><source>Cell</source><volume>161</volume><fpage>595</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.03.011</pub-id><pub-id pub-id-type="pmid">25892225</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>AG</given-names></name><name><surname>Mendoza</surname><given-names>A</given-names></name><name><surname>Hemmers</surname><given-names>S</given-names></name><name><surname>Moltedo</surname><given-names>B</given-names></name><name><surname>Niec</surname><given-names>RE</given-names></name><name><surname>Schizas</surname><given-names>M</given-names></name><name><surname>Hoyos</surname><given-names>BE</given-names></name><name><surname>Putintseva</surname><given-names>EV</given-names></name><name><surname>Chaudhry</surname><given-names>A</given-names></name><name><surname>Dikiy</surname><given-names>S</given-names></name><name><surname>Fujisawa</surname><given-names>S</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Treuting</surname><given-names>PM</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Stability and function of regulatory T cells expressing the transcription factor T-bet</article-title><source>Nature</source><volume>546</volume><fpage>421</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/nature22360</pub-id><pub-id pub-id-type="pmid">28607488</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>XX</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Wu</surname><given-names>TT</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>YC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases <italic>in Vitro</italic> and <italic>in Vivo</italic>: Regulation of Redox Biology and Mitochondrial Function</article-title><source>Frontiers in Aging Neuroscience</source><volume>10</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3389/fnagi.2018.00121</pub-id><pub-id pub-id-type="pmid">29755339</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littringer</surname><given-names>K</given-names></name><name><surname>Moresi</surname><given-names>C</given-names></name><name><surname>Rakebrandt</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Schorer</surname><given-names>M</given-names></name><name><surname>Dolowschiak</surname><given-names>T</given-names></name><name><surname>Kirchner</surname><given-names>F</given-names></name><name><surname>Rost</surname><given-names>F</given-names></name><name><surname>Keller</surname><given-names>CW</given-names></name><name><surname>McHugh</surname><given-names>D</given-names></name><name><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>Joller</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Common Features of Regulatory T Cell Specialization During Th1 Responses</article-title><source>Frontiers in Immunology</source><volume>9</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01344</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowther</surname><given-names>DE</given-names></name><name><surname>Goods</surname><given-names>BA</given-names></name><name><surname>Lucca</surname><given-names>LE</given-names></name><name><surname>Lerner</surname><given-names>BA</given-names></name><name><surname>Raddassi</surname><given-names>K</given-names></name><name><surname>van Dijk</surname><given-names>D</given-names></name><name><surname>Hernandez</surname><given-names>AL</given-names></name><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Gunel</surname><given-names>M</given-names></name><name><surname>Coric</surname><given-names>V</given-names></name><name><surname>Krishnaswamy</surname><given-names>S</given-names></name><name><surname>Love</surname><given-names>JC</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PD-1 marks dysfunctional regulatory T cells in malignant gliomas</article-title><source>JCI Insight</source><volume>1</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1172/jci.insight.85935</pub-id><pub-id pub-id-type="pmid">27182555</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Barbi</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The regulation of immune tolerance by FOXP3</article-title><source>Nature Reviews. Immunology</source><volume>17</volume><fpage>703</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.75</pub-id><pub-id pub-id-type="pmid">28757603</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukashev</surname><given-names>D</given-names></name><name><surname>Caldwell</surname><given-names>C</given-names></name><name><surname>Ohta</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Sitkovsky</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>48754</fpage><lpage>48763</lpage><pub-id pub-id-type="doi">10.1074/jbc.M104782200</pub-id><pub-id pub-id-type="pmid">11602577</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>E</given-names></name><name><surname>Goggins</surname><given-names>BJ</given-names></name><name><surname>Cardona</surname><given-names>J</given-names></name><name><surname>Cole</surname><given-names>S</given-names></name><name><surname>Minahan</surname><given-names>K</given-names></name><name><surname>Mateer</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>MM</given-names></name><name><surname>Shalwitz</surname><given-names>R</given-names></name><name><surname>Keely</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis</article-title><source>Inflammatory Bowel Diseases</source><volume>21</volume><fpage>267</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000277</pub-id><pub-id pub-id-type="pmid">25545377</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>PH</given-names></name><name><surname>Wiesener</surname><given-names>MS</given-names></name><name><surname>Chang</surname><given-names>GW</given-names></name><name><surname>Clifford</surname><given-names>SC</given-names></name><name><surname>Vaux</surname><given-names>EC</given-names></name><name><surname>Cockman</surname><given-names>ME</given-names></name><name><surname>Wykoff</surname><given-names>CC</given-names></name><name><surname>Pugh</surname><given-names>CW</given-names></name><name><surname>Maher</surname><given-names>ER</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis</article-title><source>Nature</source><volume>399</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/20459</pub-id><pub-id pub-id-type="pmid">10353251</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGettrick</surname><given-names>AF</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Role of HIF in Immunity and Inflammation</article-title><source>Cell Metabolism</source><volume>32</volume><fpage>524</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.08.002</pub-id><pub-id pub-id-type="pmid">32853548</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeown</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response</article-title><source>The British Journal of Radiology</source><volume>87</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1259/bjr.20130676</pub-id><pub-id pub-id-type="pmid">24588669</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mempel</surname><given-names>TR</given-names></name><name><surname>Marangoni</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Guidance factors orchestrating regulatory T cell positioning in tissues during development, homeostasis, and response</article-title><source>Immunological Reviews</source><volume>289</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1111/imr.12761</pub-id><pub-id pub-id-type="pmid">30977195</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meneses</surname><given-names>AM</given-names></name><name><surname>Wielockx</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PHD2: from hypoxia regulation to disease progression</article-title><source>Hypoxia (Auckland, N.Z.)</source><volume>4</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.2147/HP.S53576</pub-id><pub-id pub-id-type="pmid">27800508</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikhaylova</surname><given-names>O</given-names></name><name><surname>Ignacak</surname><given-names>ML</given-names></name><name><surname>Barankiewicz</surname><given-names>TJ</given-names></name><name><surname>Harbaugh</surname><given-names>SV</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Maxwell</surname><given-names>PH</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Van Geyte</surname><given-names>K</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Revelo</surname><given-names>MP</given-names></name><name><surname>Wyder</surname><given-names>M</given-names></name><name><surname>Greis</surname><given-names>KD</given-names></name><name><surname>Meller</surname><given-names>J</given-names></name><name><surname>Czyzyk-Krzeska</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>2701</fpage><lpage>2717</lpage><pub-id pub-id-type="doi">10.1128/MCB.01231-07</pub-id><pub-id pub-id-type="pmid">18285459</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanduri</surname><given-names>J</given-names></name><name><surname>Vaddi</surname><given-names>DR</given-names></name><name><surname>Khan</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Makarenko</surname><given-names>V</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Prabhakar</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HIF-1α activation by intermittent hypoxia requires NADPH oxidase stimulation by xanthine oxidase</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e119762</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0119762</pub-id><pub-id pub-id-type="pmid">25751622</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>DL</given-names></name><name><surname>Mahmud</surname><given-names>SA</given-names></name><name><surname>Sjaastad</surname><given-names>LE</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Spanier</surname><given-names>JA</given-names></name><name><surname>Simeonov</surname><given-names>DR</given-names></name><name><surname>Ruscher</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Proekt</surname><given-names>I</given-names></name><name><surname>Miller</surname><given-names>CN</given-names></name><name><surname>Hekim</surname><given-names>C</given-names></name><name><surname>Jeschke</surname><given-names>JC</given-names></name><name><surname>Aggarwal</surname><given-names>P</given-names></name><name><surname>Broeckel</surname><given-names>U</given-names></name><name><surname>LaRue</surname><given-names>RS</given-names></name><name><surname>Henzler</surname><given-names>CM</given-names></name><name><surname>Alegre</surname><given-names>M-L</given-names></name><name><surname>Anderson</surname><given-names>MS</given-names></name><name><surname>August</surname><given-names>A</given-names></name><name><surname>Marson</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>CB</given-names></name><name><surname>Farrar</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Thymic regulatory T cells arise via two distinct developmental programs</article-title><source>Nature Immunology</source><volume>20</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0289-6</pub-id><pub-id pub-id-type="pmid">30643267</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panduro</surname><given-names>M</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tissue Tregs</article-title><source>Annual Review of Immunology</source><volume>34</volume><fpage>609</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095948</pub-id><pub-id pub-id-type="pmid">27168246</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radu</surname><given-names>M</given-names></name><name><surname>Chernoff</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An in vivo assay to test blood vessel permeability</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><elocation-id>e50062</elocation-id><pub-id pub-id-type="doi">10.3791/50062</pub-id><pub-id pub-id-type="pmid">23524912</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redpath</surname><given-names>SA</given-names></name><name><surname>van der Werf</surname><given-names>N</given-names></name><name><surname>Cervera</surname><given-names>AM</given-names></name><name><surname>MacDonald</surname><given-names>AS</given-names></name><name><surname>Gray</surname><given-names>D</given-names></name><name><surname>Maizels</surname><given-names>RM</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection</article-title><source>European Journal of Immunology</source><volume>43</volume><fpage>705</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1002/eji.201242794</pub-id><pub-id pub-id-type="pmid">23319295</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero-Ruiz</surname><given-names>A</given-names></name><name><surname>Bautista</surname><given-names>L</given-names></name><name><surname>Navarro</surname><given-names>V</given-names></name><name><surname>Heras-Garvín</surname><given-names>A</given-names></name><name><surname>March-Díaz</surname><given-names>R</given-names></name><name><surname>Castellano</surname><given-names>A</given-names></name><name><surname>Gómez-Díaz</surname><given-names>R</given-names></name><name><surname>Castro</surname><given-names>MJ</given-names></name><name><surname>Berra</surname><given-names>E</given-names></name><name><surname>López-Barneo</surname><given-names>J</given-names></name><name><surname>Pascual</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Prolyl hydroxylase-dependent modulation of eukaryotic elongation factor 2 activity and protein translation under acute hypoxia</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>9651</fpage><lpage>9658</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.299180</pub-id><pub-id pub-id-type="pmid">22308030</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubtsov</surname><given-names>YP</given-names></name><name><surname>Rasmussen</surname><given-names>JP</given-names></name><name><surname>Chi</surname><given-names>EY</given-names></name><name><surname>Fontenot</surname><given-names>J</given-names></name><name><surname>Castelli</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Treuting</surname><given-names>P</given-names></name><name><surname>Siewe</surname><given-names>L</given-names></name><name><surname>Roers</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>WR</given-names><suffix>Jr</suffix></name><name><surname>Muller</surname><given-names>W</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces</article-title><source>Immunity</source><volume>28</volume><fpage>546</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.017</pub-id><pub-id pub-id-type="pmid">18387831</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samstein</surname><given-names>RM</given-names></name><name><surname>Josefowicz</surname><given-names>SZ</given-names></name><name><surname>Arvey</surname><given-names>A</given-names></name><name><surname>Treuting</surname><given-names>PM</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict</article-title><source>Cell</source><volume>150</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.05.031</pub-id><pub-id pub-id-type="pmid">22770213</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GLH</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus</article-title><source>Cell</source><volume>107</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(01)00518-9</pub-id><pub-id pub-id-type="pmid">11595178</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shehade</surname><given-names>H</given-names></name><name><surname>Acolty</surname><given-names>V</given-names></name><name><surname>Moser</surname><given-names>M</given-names></name><name><surname>Oldenhove</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cutting Edge: Hypoxia-Inducible Factor 1 Negatively Regulates Th1 Function</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>195</volume><fpage>1372</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402552</pub-id><pub-id pub-id-type="pmid">26179900</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shevyrev</surname><given-names>D</given-names></name><name><surname>Tereshchenko</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Treg Heterogeneity, Function, and Homeostasis</article-title><source>Frontiers in Immunology</source><volume>10</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.03100</pub-id><pub-id pub-id-type="pmid">31993063</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>LZ</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>1367</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1084/jem.20110278</pub-id><pub-id pub-id-type="pmid">21708926</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity</article-title><source>Frontiers in Immunology</source><volume>10</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02716</pub-id><pub-id pub-id-type="pmid">31921097</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talks</surname><given-names>KL</given-names></name><name><surname>Turley</surname><given-names>H</given-names></name><name><surname>Gatter</surname><given-names>KC</given-names></name><name><surname>Maxwell</surname><given-names>PH</given-names></name><name><surname>Pugh</surname><given-names>CW</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages</article-title><source>The American Journal of Pathology</source><volume>157</volume><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/s0002-9440(10)64554-3</pub-id><pub-id pub-id-type="pmid">10934146</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>CL</given-names></name><name><surname>Kuchroo</surname><given-names>JR</given-names></name><name><surname>Sage</surname><given-names>PT</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Francisco</surname><given-names>LM</given-names></name><name><surname>Buck</surname><given-names>J</given-names></name><name><surname>Thaker</surname><given-names>YR</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>McArdel</surname><given-names>SL</given-names></name><name><surname>Juneja</surname><given-names>VR</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Lovitch</surname><given-names>SB</given-names></name><name><surname>Lian</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>GF</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name><name><surname>Vignali</surname><given-names>DAA</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20182232</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20182232</pub-id><pub-id pub-id-type="pmid">33045061</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Shitara</surname><given-names>K</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Regulatory T cells in cancer immunosuppression - implications for anticancer therapy</article-title><source>Nature Reviews. Clinical Oncology</source><volume>16</volume><fpage>356</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1038/s41571-019-0175-7</pub-id><pub-id pub-id-type="pmid">30705439</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Burg</surname><given-names>SH</given-names></name><name><surname>Piersma</surname><given-names>SJ</given-names></name><name><surname>de Jong</surname><given-names>A</given-names></name><name><surname>van der Hulst</surname><given-names>JM</given-names></name><name><surname>Kwappenberg</surname><given-names>KMC</given-names></name><name><surname>van den Hende</surname><given-names>M</given-names></name><name><surname>Welters</surname><given-names>MJP</given-names></name><name><surname>Van Rood</surname><given-names>JJ</given-names></name><name><surname>Fleuren</surname><given-names>GJ</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name><name><surname>Kenter</surname><given-names>GG</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens</article-title><source>PNAS</source><volume>104</volume><fpage>12087</fpage><lpage>12092</lpage><pub-id pub-id-type="doi">10.1073/pnas.0704672104</pub-id><pub-id pub-id-type="pmid">17615234</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vignali</surname><given-names>DAA</given-names></name><name><surname>Collison</surname><given-names>LW</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>How regulatory T cells work</article-title><source>Nature Reviews. Immunology</source><volume>8</volume><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nri2343</pub-id><pub-id pub-id-type="pmid">18566595</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GL</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Purification and characterization of hypoxia-inducible factor 1</article-title><source>The Journal of Biological Chemistry</source><volume>270</volume><fpage>1230</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.3.1230</pub-id><pub-id pub-id-type="pmid">7836384</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardell</surname><given-names>CM</given-names></name><name><surname>MacDonald</surname><given-names>KN</given-names></name><name><surname>Levings</surname><given-names>MK</given-names></name><name><surname>Cook</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cross talk between human regulatory T cells and antigen-presenting cells: Lessons for clinical applications</article-title><source>European Journal of Immunology</source><volume>51</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/eji.202048746</pub-id><pub-id pub-id-type="pmid">33301176</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>ER</given-names></name><name><surname>Walmsley</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inflammation and Hypoxia: HIF and PHD Isoform Selectivity</article-title><source>Trends in Molecular Medicine</source><volume>25</volume><fpage>33</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2018.10.006</pub-id><pub-id pub-id-type="pmid">30442494</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>JD</given-names></name><name><surname>Coleman</surname><given-names>ML</given-names></name><name><surname>Pugh</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing</article-title><source>Cellular and Molecular Life Sciences</source><volume>66</volume><fpage>3539</fpage><lpage>3554</lpage><pub-id pub-id-type="doi">10.1007/s00018-009-0147-7</pub-id><pub-id pub-id-type="pmid">19756382</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlfert</surname><given-names>EA</given-names></name><name><surname>Warunek</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>RM</given-names></name><name><surname>Marzullo</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tbet - expressing Tregs protect against lethal immunopathology during <italic>T. gondii</italic> infection</article-title><source>Journal of Immunology</source><volume>5</volume><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.4049/immunohorizons.2100080</pub-id><pub-id pub-id-type="pmid">34893511</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Pi</surname><given-names>X</given-names></name><name><surname>Townley-Tilson</surname><given-names>WHD</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Wehrens</surname><given-names>XHT</given-names></name><name><surname>Entman</surname><given-names>ML</given-names></name><name><surname>Taffet</surname><given-names>GE</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Schisler</surname><given-names>JC</given-names></name><name><surname>Meissner</surname><given-names>G</given-names></name><name><surname>Patterson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PHD2/3-dependent hydroxylation tunes cardiac response to β-adrenergic stress via phospholamban</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>2759</fpage><lpage>2771</lpage><pub-id pub-id-type="doi">10.1172/JCI80369</pub-id><pub-id pub-id-type="pmid">26075818</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>T-cell tolerance: central and peripheral</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1101/cshperspect.a006957</pub-id><pub-id pub-id-type="pmid">22661634</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>A</given-names></name><name><surname>Hester</surname><given-names>J</given-names></name><name><surname>Macklin</surname><given-names>PS</given-names></name><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Uchiyama</surname><given-names>M</given-names></name><name><surname>Biggs</surname><given-names>D</given-names></name><name><surname>Bishop</surname><given-names>T</given-names></name><name><surname>Bull</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Cawthorne</surname><given-names>E</given-names></name><name><surname>Coleman</surname><given-names>ML</given-names></name><name><surname>Crockford</surname><given-names>TL</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Dow</surname><given-names>LE</given-names></name><name><surname>Goldin</surname><given-names>R</given-names></name><name><surname>Kranc</surname><given-names>K</given-names></name><name><surname>Kudo</surname><given-names>H</given-names></name><name><surname>Lawson</surname><given-names>H</given-names></name><name><surname>McAuliffe</surname><given-names>J</given-names></name><name><surname>Milward</surname><given-names>K</given-names></name><name><surname>Scudamore</surname><given-names>CL</given-names></name><name><surname>Soilleux</surname><given-names>E</given-names></name><name><surname>Issa</surname><given-names>F</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name><name><surname>Pugh</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Systemic silencing of PHD2 causes reversible immune regulatory dysfunction</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>3640</fpage><lpage>3656</lpage><pub-id pub-id-type="doi">10.1172/JCI124099</pub-id><pub-id pub-id-type="pmid">31162141</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70555.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ratcliffe</surname><given-names>Peter J</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.03.23.436597" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.03.23.436597"/></front-stub><body><p>The possibility that hypoxia signaling pathways exert control over immunity by actions on regulatory T lymphocytes is of great interest given that immune inflammatory pathology is often associated with hypoxia. This article supports the cell-intrinsic role of a specific isoform of hypoxia-inducible factor 2 (HIF2) in reducing the function of these cells when HIF is activated by inactivation of its regulatory hydroxylase. Aside from the biology, this is important because both HIF activators and specific HIF-2 inhibitors are in use clinically.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70555.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ratcliffe</surname><given-names>Peter J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Pugh</surname><given-names>Chris</given-names></name><role>Reviewer</role></contrib><contrib contrib-type="reviewer"><name><surname>Johnson</surname><given-names>Randall</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.03.23.436597">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.03.23.436597v3">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;The oxygen sensor Prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Chris Pugh (Reviewer #1); Randall Johnson (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Your manuscript has now been carefully reviewed for <italic>eLife</italic> and the reviewers have debated their somewhat different perspectives.</p><p>You will see from the correspondence that though all considered that the manuscript contains useful data on the important question as to whether activity of the HIF hydroxylase system directs regulatory T cell function in accordance with oxygen availability. Nevertheless, there were differences of opinion on the extent to which your findings advance knowledge on this question.</p><p>My summary of this is that the overall view (and my own view) is that there is merit in publishing the current extensive datasets that you have obtained, not least in the interests of consolidating findings in a complex but important area. We ask however that you address all specific questions raised by the reviewers as part of the publication process.</p><p>Decision to publish would be subject to satisfactory responses. In particular, it is essential that you address the following with changes to the manuscript:</p><p>(i) For proper presentation to a general audience, it is necessary that you present the existing published literature that is directly relevant to your work in the introduction. This enables your results to be understood in the context of that literature. Your discussion may then concentrate on differences/similarities/extensions of that work by your own data and on whether the overarching question of the role of physiological/pathological signalling in directing T-reg activity has or has not been answered by the literature in total.</p><p>(ii) An important part of the novelty is dependent on restriction of recombination using the Foxp3-Cre-YFP line. More data is needed to show that recombination is indeed restricted as proposed, or that additional sites of recombination might contribute to the phenotype if they exist.</p><p>(iii) It is necessary to provide more detailed description of the haemorragic abdomen – in particular, whether this might imply a more complex phenotype affecting other components of haematopoiesis.</p><p>(iv) All reviewers felt more data was required to support the mechanistic hypotheses. However, it was acknowledged that this would likely demand an unrealistic amount of further work. The authors should therefore either provide any further experiment support they can, or moderate the mechanistic claims. In particular, they should address the issue raised by one of the reviewers that changes in splenic architecture could have confounded interpretation of the importance of lymphocyte mislocalization in that organ.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Please add more description of the existing literature describing effects of disruption of HIF-signalling on Treg function to the Introduction and identify (and discuss possible explanations for) similarities and differences between these reports and your own data in the Discussion.</p><p>Please clarify expression of YFP outside the Treg lineage and any changes in Phd2 expression in non-lymphoid tissues (including endothelium, liver and colon). Please comment on the relative changes in red and white pulp of the spleen and provide data to show whether haematocrit has or has not changed in the Phd2-deficient Treg mice.</p><p>Please specify the sex of animals used in all the experiments.</p><p>Please indicate absolute cell counts as well as percentages in the various lymphoid organs.</p><p>It would be nice if critical gating strategies were shown to support the flow cytometry analyses.</p><p>I think there are a number of places where the authors could indicate some caveats to their interpretation of their results, many of which should be apparent from my public review.</p><p>I would like to consider further specific recommendations to Authors in the light of discussion of the public review with my co-reviewers and the Reviewing Editor.</p><p>Typos and issues of clarity</p><p>P4 para 1 'prolin-hydroxylation' should be 'prolyl-hydroxylation'</p><p>In describing Figure S1 the statement is made 'Spontaneous expression of GLUT1, a well-known target of HIF1α, was also only found in Foxp3-expressing cells in these mice, further supporting the selective depletion of PHD2 in Tregs (Figure S1).' Is the effect not one of up-regulation rather than expression?</p><p>The authors' surnames should be completed in reference 22.</p><p>Availability of raw data.</p><p>Please make the raw data for the work presented in Figure 6 and all the Supplementary Figures publically available. Please make it clear how to access all aspects of publically available data in the text.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Despite this not being necessary for the publication of this manuscript, my only suggestion to the authors is to test effect of chemical PHD inhibitor drugs on TREG function and use the specific HIF2 inhibitor PT-2385 to try and abolish any potential side effect. Additionally, the use of PT2385 per se in any of the in vivo assays with the TREG PHD2 KO cells would not only rule out any cellular adaptation mechanism that might occur during TREG development in double or triple KOs and would be relevant for the clinic as this inhibitor is being tested in humans.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. The authors should analyze the early Treg development in the thymus.</p><p>2. Extrinsic vs. intrinsic effect should be addressed using Foxp3-cre +/- mice, or co-adoptive transfer approaches.</p><p>3. The authors should perform more experiments to clarify the mis-localization vs. direct suppression in vivo. The current model does not explain the effector/TH1-like phenotype.</p><p>4. More mechanistic experiments are required to address the PHD2-HIF2s relation to the Stat1 phosphorylation, and the mis-localization issue.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70555.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Decision to publish would be subject to satisfactory responses. In particular, it is essential that you address the following with changes to the manuscript:</p><p>(i) For proper presentation to a general audience, it is necessary that you present the existing published literature that is directly relevant to your work in the introduction. This enables your results to be understood in the context of that literature. Your discussion may then concentrate on differences/similarities/extensions of that work by your own data and on whether the overarching question of the role of physiological/pathological signalling in directing T-reg activity has or has not been answered by the literature in total.</p></disp-quote><p>We have followed this recommendation and provided additional information on the “state of the art” and previous work covering the topic of our work. This is now included in the Introduction section.</p><disp-quote content-type="editor-comment"><p>(ii) An important part of the novelty is dependent on restriction of recombination using the Foxp3-Cre-YFP line. More data is needed to show that recombination is indeed restricted as proposed, or that additional sites of recombination might contribute to the phenotype if they exist.</p></disp-quote><p>This point is well taken. As previously stated in our previous version, expression of the Cre-allele appears as highly restricted to the Foxp3<sup>+</sup> subset of lymphoid cells. As expected however, we have found and reported in Figure 8-figure supplement 1 that a minor, but identifiable subset of non-lymphoid (CD45-negative) cells (from 1 to 5%, depending on the organ considered) expresses the Cre allele. Despite our efforts, we could not identify the nature of these cells, and their contribution to the observed phenotype remains therefore to be established. We do however believe that (i) the fact that PHD2-KO Tregs display a reduced suppressive capacity when co-transferred with naïve T cells in Rag2-deficient mice (Figure 4) and (ii) the observations performed in heterozygous Foxp3<sup>Cre/+</sup> Egln1<sup>fl/fl</sup> (Figure 3) demonstrating that loss of PHD2 expression affects the Treg phenotype in a cell-autonomous, intrinsic fashion, strongly indicate that PHD2-expression is required for adequate Treg phenotype and function irrespectively of the environment in which they differentiate.</p><disp-quote content-type="editor-comment"><p>(iii) It is necessary to provide more detailed description of the haemorragic abdomen – in particular, whether this might imply a more complex phenotype affecting other components of haematopoiesis.</p></disp-quote><p>We have been able to demonstrate that these mice display an increased haematocrit and enhanced vascular permeability that could be a consequence of enhanced Vegfa expression by Tregs. At present, the mechanism leading to these haematological consequences remain to be established. Notably however, an haemorrhagic abdomen was not observed in all mice examined (albeit in a majority of them, approximatively 70%), whereas the phenotypical alterations of Tregs and the enhanced activation of Tconvs were confirmed in all animals displaying PHD2-deficient Tregs, once again suggesting that the effect of PHD2 on Treg biology are not a consequence of altered haematological parameters.</p><disp-quote content-type="editor-comment"><p>(iv) All reviewers felt more data was required to support the mechanistic hypotheses. However, it was acknowledged that this would likely demand an unrealistic amount of further work. The authors should therefore either provide any further experiment support they can, or moderate the mechanistic claims. In particular, they should address the issue raised by one of the reviewers that changes in splenic architecture could have confounded interpretation of the importance of lymphocyte mislocalization in that organ.</p></disp-quote><p>This point is well taken, and we have now deleted the last figure of the manuscript and provided a less speculative conclusion to our study. We pointed to a possible link between the PHD2-HIF2α axis and STAT1 activation as an important factor regulating Treg phenotype and function.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Please add more description of the existing literature describing effects of disruption of HIF-signalling on Treg function to the Introduction and identify (and discuss possible explanations for) similarities and differences between these reports and your own data in the Discussion.</p></disp-quote><p>We believe we have adequately responded to this request</p><disp-quote content-type="editor-comment"><p>Please clarify expression of YFP outside the Treg lineage and any changes in Phd2 expression in non-lymphoid tissues (including endothelium, liver and colon). Please comment on the relative changes in red and white pulp of the spleen and provide data to show whether haematocrit has or has not changed in the Phd2-deficient Treg mice.</p></disp-quote><p>We have performed the requested experiments but could not achieve a definite conclusion regarding the cause of the haematological abnormalities observed in PHD2<sup>ΔTregs</sup> mice.</p><disp-quote content-type="editor-comment"><p>Please indicate absolute cell counts as well as percentages in the various lymphoid organs.</p></disp-quote><p>An example of absolute cells counts is now provided in the Figure 1—figure supplement 4.</p><disp-quote content-type="editor-comment"><p>It would be nice if critical gating strategies were shown to support the flow cytometry analyses.</p></disp-quote><p>An example of the gating strategy used throughout this study is now provided in Figure 1—figure supplement 3</p><disp-quote content-type="editor-comment"><p>Availability of raw data.</p></disp-quote><p>All raw data are now available, see Excel Source data.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Despite this not being necessary for the publication of this manuscript, my only suggestion to the authors is to test effect of chemical PHD inhibitor drugs on TREG function and use the specific HIF2 inhibitor PT-2385 to try and abolish any potential side effect. Additionally, the use of PT2385 per se in any of the in vivo assays with the TREG PHD2 KO cells would not only rule out any cellular adaptation mechanism that might occur during TREG development in double or triple KOs and would be relevant for the clinic as this inhibitor is being tested in humans.</p></disp-quote><p>We thank the reviewer for this interesting suggestion that we will take into consideration for our future work</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. The authors should analyze the early Treg development in the thymus.</p></disp-quote><p>We thank you the reviewer for this insightful suggestion. We have now analysed the frequency of thymic Treg precursors (see Figure 2 b-d) and found an increased frequency of immature Tregs displaying the Foxp3<sup>lo</sup> CD25<sup>neg</sup> phenotype in the thymus of PHD2<sup>ΔTregs</sup> mice. Consistent with the expected tissue distribution of the Cre allele, no differences were found in the frequency of the Foxp3<sup>neg</sup> CD25<sup>pos</sup> subset of precursor Tregs. Overall, this analysis suggests a role for PHD2 in thymic Treg development and a possible “immature-like” state of peripheral Tregs in PHD2<sup>ΔTregs</sup> mice.</p><disp-quote content-type="editor-comment"><p>2. Extrinsic vs. intrinsic effect should be addressed using Foxp3-cre +/- mice, or co-adoptive transfer approaches.</p></disp-quote><p>We thank again the reviewer for this suggestion. The results from these experiments are now depicted in Figure 3, and demonstrate that the phenotypic alterations found in PHD2-deficient Tregs appear as “cell autonomous”. Moreover, this experiment also strongly suggest that PHD2-deficient T cells display reduced fitness when compared to their WT counterpart, a finding that we have been able to confirm in adoptive co-transfer experiments (data not shown).</p><disp-quote content-type="editor-comment"><p>3. The authors should perform more experiments to clarify the mis-localization vs. direct suppression in vivo. The current model does not explain the effector/TH1-like phenotype.</p></disp-quote><p>This comment is well taken, and as previously discussed (see remark n°8), we are now convinced that our work does not provide sufficient arguments to sustain the “mis-localisation” hypothesis, partly due to the unresolved question of the profound changes in spleen cell morphology observed in PHD2<sup>ΔTregs</sup> mice. We have therefore omitted this set of data from the present version of the manuscript.</p><disp-quote content-type="editor-comment"><p>4. More mechanistic experiments are required to address the PHD2-HIF2s relation to the Stat1 phosphorylation, and the mis-localization issue.</p></disp-quote><p>We fully agree with this final remark, but the amount of work that would be required to experimentally connect HIF2α to STAT1 activation is probably beyond reach within the time allowed for this review. In particular it appears, from the literature, that STAT1 regulation is a complex phenomenon involving a set of post-translational modifications (including methylation and palmitoylation) that could represent targets of HIF2α-mediated regulation.</p></body></sub-article></article>